Document:

EX-10.1

 Exhibit 10.1 

EXECUTION VERSION 
 SHARE
PURCHASE AGREEMENT 
 BY AND AMONG 

TAXUS CARDIUM PHARMACEUTICALS GROUP, INC., 

ANGIONETICS, INC. 
 AND

 PINEWORLD CAPITAL LIMITED 

Dated as of June 7, 2016 

 EXECUTION VERSION 

TABLE OF CONTENTS 
  

									
	 	 	 	  	 	  	Page	 
		
	SECTION 1 DEFINITIONS AND INTERPRETATIONS	  	 	1	  
		 	1.1	  	Definitions	  	 	1	  
		 	1.2	  	Certain Interpretations	  	 	5	  
		
	SECTION 2 PURCHASE AND SALE OF THE SHARES; CLOSING DELIVERIES	  	 	6	  
		 	2.1	  	Purchase and Sale of the Shares	  	 	6	  
		 	2.2	  	Closing Deliveries	  	 	7	  
		
	SECTION 3 REPRESENTATIONS AND WARRANTIES OF CARDIUM AND ANGIONETICS	  	 	7	  
		 	3.1	  	Organization	  	 	7	  
		 	3.2	  	Authority	  	 	7	  
		 	3.3	  	Subsidiaries	  	 	8	  
		 	3.4	  	No Conflicts	  	 	8	  
		 	3.5	  	Governmental Filings and Consents	  	 	8	  
		 	3.6	  	Angionetics Capital Structure	  	 	8	  
		 	3.7	  	Financial Statements	  	 	9	  
		 	3.8	  	Absence of Changes	  	 	9	  
		 	3.9	  	Taxes	  	 	10	  
		 	3.10	  	Litigation	  	 	10	  
		 	3.11	  	Title to Assets: Property	  	 	10	  
		 	3.12	  	Contracts	  	 	11	  
		 	3.13	  	Intellectual Property	  	 	13	  
		 	3.14	  	Personnel	  	 	13	  
		 	3.15	  	Employee Benefit Plans	  	 	14	  
		 	3.16	  	Compliance with Laws; Permits	  	 	15	  
		 	3.17	  	Certain Relationships and Related Transactions	  	 	15	  
		 	3.18	  	Insurance	  	 	15	  
		 	3.19	  	Obligations of Management	  	 	16	  
		 	3.20	  	Registration and Voting Rights	  	 	16	  
		 	3.21	  	Disclosure	  	 	16	  
		 	3.22	  	Brokers and Finders	  	 	16	  
		 	3.23	  	No “Bad Actor” Disqualification	  	 	16	  
		
	SECTION 4 REPRESENTATIONS AND WARRANTIES BY INVESTOR	  	 	16	  
		 	4.1	  	Organization	  	 	16	  
		 	4.2	  	Authority	  	 	16	  
		 	4.3	  	No Conflicts	  	 	17	  
		 	4.4	  	Governmental Filings and Consents	  	 	17	  
		 	4.5	  	No Registration	  	 	17	  
		 	4.6	  	Investment Intent	  	 	17	  
		 	4.7	  	Investment Experience	  	 	17	  
		 	4.8	  	Speculative Nature of Investment	  	 	18	  
		 	4.9	  	Access to Information	  	 	18	  
		 	4.10	  	Securities Law Compliance	  	 	18	  
		 	4.11    	  	Brokers and Finders	  	 	18	  

  
 -i- 

 EXECUTION VERSION 
  

									
	 	 	 	  	 	  	Page	 
		
	SECTION 5 ADDITIONAL AGREEMENTS	  	 	18	  
		 	5.1	  	Right of First Refusal	  	 	18	  
		 	5.2	  	Tag-along Rights	  	 	19	  
		 	5.3	  	Survival of Representations and Warranties	  	 	20	  
		 	5.4	  	Indemnification	  	 	21	  
		 	5.5	  	Certain Payments	  	 	21	  
		 	5.6	  	Refund of Term Sheet Fee	  	 	22	  
		
	SECTION 6	  	 	22	  
		
	CONDITIONS TO CLOSING	  	 	22	  
		 	6.1	  	Conditions to Obligations of All Parties	  	 	22	  
		 	6.2	  	Conditions to Obligations of Investor	  	 	22	  
		 	6.3	  	Conditions to Obligations of Angionetics	  	 	23	  
		
	SECTION 7	  	 	24	  
		
	TERMINATION	  	 	24	  
		 	7.1	  	Termination	  	 	24	  
		 	7.2	  	Effect of Termination	  	 	25	  
		
	SECTION 8 MISCELLANEOUS	  	 	25	  
		 	8.1	  	Further Assurances	  	 	25	  
		 	8.2	  	Notices	  	 	25	  
		 	8.3	  	Fees and Expenses	  	 	25	  
		 	8.4	  	Successors and Assigns	  	 	25	  
		 	8.5	  	Third Parties	  	 	26	  
		 	8.6	  	Entire Agreement	  	 	26	  
		 	8.7	  	Amendments	  	 	26	  
		 	8.8	  	No Delays or Omissions	  	 	26	  
		 	8.9	  	Governing Law	  	 	26	  
		 	8.10	  	Jurisdiction; Venue	  	 	26	  
		 	8.11	  	Attorneys’ Fees	  	 	26	  
		 	8.12    	  	Counterparts	  	 	26	  

  
 -ii- 

 EXECUTION VERSION 
  

 EXHIBITS 

Exhibit A – Certificate of Designation of Series A Convertible Preferred Stock 

Exhibit B – Investor Rights Agreement 
 Exhibit C –
License Agreement 
 Exhibit D – Term Sheet, as amended 

Exhibit E – Form of Opinion of Counsel for Cardium and Angionetics 

  
 -iii- 

 EXECUTION VERSION 

SHARE PURCHASE AGREEMENT 

THIS SHARE PURCHASE AGREEMENT (this
“Agreement”) is made and entered into as of June 7, 2016, by and among Taxus Cardium Pharmaceuticals Group, Inc., a Delaware corporation (“Cardium”), Angionetics, Inc., a Delaware corporation
(“Angionetics”) and Pineworld Capital Limited, a Hong Kong limited liability company ( “Investor”), with respect to the following facts:. 

A. Cardium is the beneficial and registered owner of the entire issued share capital of Angionetics. 

B. Angionetics desires to sell to Investor, and Investor desires to purchase from Cardium, 600,000 shares (the “Shares”) of
Angionetics’ Series A Convertible Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), with the rights, privileges and preferences set forth in the Certificate of Designation attached hereto as
Exhibit A (the “Certificate of Designation”) on the terms and conditions contained in this Agreement. 
 C.
Angionetics and Investor are concurrently entering into that certain Investors Rights Agreement of even date herewith in the form attached hereto as Exhibit B (the “Investors Rights Agreement”) and that certain License
Agreement of even date herewith in the form attached hereto as Exhibit C (the “License Agreement”). 
 NOW,
THEREFORE, in consideration of the foregoing premises and the mutual representations, warranties, covenants and agreements herein contained, and intending to be legally bound hereby, the parties agree as follows: 

SECTION 1 

DEFINITIONS AND INTERPRETATIONS 

1.1 Definitions. The terms used in this Agreement shall have the meanings ascribed thereto herein. When a term is used, but not
defined, in a Schedule or Appendix to this Agreement, it shall have the meaning ascribed thereto in this Agreement. 

“Action” means any action, suit, claim, charge, demand, cause of action or suit (whether in contract or tort or otherwise),
litigation (whether at law or in equity, whether civil or criminal), controversy, assessment, arbitration, investigation, audit, hearing, complaint or other proceeding. 

“Affiliate” means, with respect to any Person, (a) if such Person is a natural Person, a spouse of such Person, or any
child or parent of such Person, and (b) if such Person is not a natural Person, any Person directly or indirectly controlling or controlled by or under direct or indirect common control with such Person, where “control” means the
possession, directly or indirectly, of the power to direct the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. With respect to Investor, Affiliate shall include a company or other
entity that is controlled by, or under common control with Huapont Life Sciences Co. Ltd. or its shareholders, Zhang Songshan or Zhang Yizhuo. 

“Agreement” has the meaning set forth in the Preamble. 

“Bad Actor Disqualification” means any of the “bad actor” disqualifications described in Rule 506(d)(1)(i) through
(viii) under the Securities Act. 

  
 -1- 

 EXECUTION VERSION 
  

 “Business” means the business of Angionetics as it currently is conducted
and as currently proposed to be conducted. 
 “Business Day” means any day that is not a Saturday, a Sunday or other day on
which commercial banks in San Diego, California are authorized or obligated by Law to close. 
 “Cardium” has the meaning
set forth in the Preamble. 
 “Code” means the Internal Revenue Code of 1986, as amended. 

“Common Stock” means the Angionetics Common Stock, par value $0.0001 per share. 

“Conflict” means, with respect to any Person, any action that will contravene, conflict with or result in any violation of or
default under (with or without notice or lapse of time, or both) or give rise to a right of termination, cancellation, modification or acceleration of any obligation or loss of any benefit, result in the creation or imposition of any Lien under or
impair such Person’s or its Subsidiaries’ rights or alter the rights or obligations of a third party with respect to the matter in question. 

“Contract” shall mean any written or oral contract, agreement, arrangement, instrument, commitment or undertaking of any
nature (including leases, licenses, mortgages, notes, guarantees, sublicenses, subcontracts, letters of intent and purchase orders). 

“Conversion Shares” shall mean the shares of Common Stock issuable upon conversion of the Shares. 

“Damages” means damage, loss, Liability, claim, deficiency, Tax, judgment, fine, penalty, interest, cost, fine, penalty,
charge, fees or other expense (including reasonable attorneys’, consultants’ and experts’ fees and expenses), directly or indirectly paid, sustained or incurred by an applicable party. 

“Disclosure Schedule” has the meaning set forth in Section 3. 

“Employee” shall mean any current or former or retired employee, director or officer of Angionetics or Cardium, as
applicable. 
 “Employee Plan” shall mean any plan, program, policy, practice, contract, agreement or other arrangement
providing for compensation, bonus pay, severance, benefits, termination pay, change of control pay, deferred compensation, performance awards, long-term incentive plan, share incentive plan, share option scheme, stock or stock related awards,
phantom stock, commission, vacation, profit sharing, pension benefits, welfare benefits, material fringe benefits or other employee benefits or remuneration of any kind, whether written or unwritten, funded or unfunded, which is or has been
maintained, contributed to, or required to be contributed to, by Cardium or Angionetics for the benefit of any Employee and with respect to which Angionetics has any Liability or obligation. 

“Financial Statements” has the meaning set forth in Section 3.7. 

“Fundamental Representation” means (i) with respect to Cardium and Angionetics, the representations contained in
Section 3.1 (Organization), Section 3.2 (Authority), Section 3.4 (No Conflict), Section 3.5 (Government Filings and Consents), Section 3.6 (Angionetics Capital

  
 -2- 

 EXECUTION VERSION 
  

 
Structure); and (ii) with respect to Investor means the representations contained in Section 4.1 (Organization) and Section 4.2 (Authority). 

“Governmental Authority” shall mean any federal, state, municipal, national, multinational, governmental public body, local
or any foreign government, or political subdivision thereof, or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or Taxing Authority or power, any court or tribunal (or
any department, bureau or division thereof), or any arbitrator or arbitral body. 
 “Guarantee” of or by any Person shall
mean any obligation, contingent or otherwise, of such Person guaranteeing any Indebtedness of any other Person (the “Primary Obligor”) in any manner, whether directly or indirectly, and including any obligation of such Person,
direct or indirect, (a) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or to purchase (or to advance or supply funds for the purchase of) any security for the payment of such Indebtedness,
(b) to purchase property, securities or services for the purpose of assuring the owner of such Indebtedness of the payment of such Indebtedness or (c) to maintain working capital, equity capital or other financial statement condition or
liquidity of the Primary Obligor so as to enable the Primary Obligor to pay such Indebtedness; provided, however, that the term Guarantee shall not include endorsements for collection or deposit, in each case in the ordinary course of business. 

“Indebtedness” shall mean all Liabilities, without duplication (including any applicable interest and premiums, penalties,
fees, expenses, costs, or payments) (i) for borrowed money, (ii) evidenced by notes, bonds, debentures or similar instruments, (iii) for the deferred purchase price of property, goods or services, (iv) under capital leases,
(v) under any letter of credit, banker’s acceptance or similar transaction, (vi) under any foreign exchange contract or other similar agreement designed to protect against fluctuations in currency value, (vii) under deferred
compensation, consulting or noncompetition agreements, (viii) under severance plans, bonus plans or similar arrangements, triggered or made payable as a result of the transactions contemplated hereby, or (ix) in the nature of guarantees of
the obligations described in the preceding clauses (i)–(viii), inclusive, of any other Person. For the avoidance of doubt, any termination or other fee payable in connection with the termination or repayment of any Indebtedness or otherwise
arising in connection with this Agreement under the terms of such Indebtedness, shall constitute Indebtedness. 
 “Intellectual
Property” means any and all of the following in any jurisdiction throughout the world: (i) trademarks and service marks, including all applications and registrations and the goodwill connected with the use of and symbolized by the
foregoing; (ii) copyrights, including all applications and registrations related to the foregoing; (iii) trade secrets and confidential know-how; (iv) patents and patent applications; (v) internet domain name registrations; and
(vi) other intellectual property and related proprietary rights, interests and protections. 
 “Intercompany
Agreements” has the meaning set forth in Section 3.12(q). 
 “Interim Balance Sheet” has the meaning
set forth in Section 3.7. 
 “IRS” means the United States Internal Revenue Service. 

“Knowledge of Angionetics” means the actual knowledge, after reasonable inquiry of those Employees of Angionetics and the
advisors of Angionetics who are aware of this 

  
 -3- 

 EXECUTION VERSION 
  

 
transaction, in each case, that would be reasonably expected to have knowledge of the matter in question, of Christopher J. Reinhard, Duane Linstrom and Lois Chandler. 

“Knowledge of Cardium” means the actual knowledge, after reasonable inquiry of those Employees of Cardium and the advisors of
Cardium who are aware of this transaction, in each case, that would be reasonably expected to have knowledge of the matter in question, of Christopher J. Reinhard, Duane Linstrom and Lois Chandler. 

“Law” or “Laws” means federal, state, municipal or local, foreign, supranational (including without
limitation laws of the European Union) or other laws, statutes, constitutions, treaties, principles of common law, directive, standard ordinances, codes, edicts resolutions, promulgations, rules, regulations, orders, judgments, rulings, writs,
injunctions, decrees, or any other similar legal requirements issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Authority. 

“Liabilities” shall mean, with respect to any Person, any and all liabilities and obligations of any kind (whether known or
unknown, contingent, accrued, unaccrued, due or to become due, secured or unsecured, matured or otherwise), including accounts payable, all liabilities and obligations related to Indebtedness or Guarantees, costs, expenses, royalties payable, and
other reserves, accrued bonuses and commissions, accrued vacation and any other form of leave, termination payment obligations, employee expense obligations and all other liabilities and obligations of such Person or any of its Subsidiaries or
Affiliates, regardless of whether such liabilities are required to be reflected on a balance sheet in accordance with US GAAP. 

“Lien” means any lien, statutory lien, pledge, mortgage, security interest, charge, claim, encumbrance, right of pre-emption,
right of first refusal, easement, right of way, covenant, restriction, right, lease, trust, order, decree, title defect, option, conditional sale or other title retention agreement or any other security interest or continuing conflicting claim of
ownership or right to use or any other third party rights of any kind or nature (or any agreement or arrangement to create any of them). 

“Material Contract” or “Material Contracts” has the meaning set forth in Section 3.12. 

“Organizational Documents” means, the memorandum of association, articles of association and similar organization documents
of an entity, as amended. 
 “Permits” means all permits, concessions, grants, franchises, licenses and other governmental
authorizations and approvals. 
 “Person” means any natural person, company, corporation, limited liability company,
general or limited partnership, trust, proprietorship, joint venture, or other business entity, unincorporated association, organization or enterprise, or any Governmental Authority. 

“Related Agreements” means Investors’ Rights Agreement and the License Agreement and all other agreements, documents,
consents, instruments and certificates entered or delivered in connection with the transactions contemplated herein by or on behalf of Cardium, Angionetics or Investor. 

“Related Party” means any current or former shareholder, Employee, officer, director of Angionetics, or any of their
Affiliates or Representatives. 

  
 -4- 

 EXECUTION VERSION 
  

 “Representative” shall mean with respect to a Person, such Person’s
officers, shareholders, employees, directors, employees, Affiliates, investment bankers, attorneys, accountants, or other agents, advisors or representatives. 

“Securities Act” means the United States Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. 
 “Series A Preferred Stock” has the meaning set forth in the Recitals. 

“Subsidiary” means, with respect to any party, any corporation or other organization, whether incorporated or unincorporated,
of which (i) at least a majority of the securities or other interests having by their terms ordinary voting power to elect a majority of the board of directors or others performing similar functions with respect to such corporation or other
organization is directly or indirectly owned or controlled by such party, corporation or organization or by any one or more of its subsidiaries or (ii) such party, corporation or organization or any other subsidiary of such party, corporation
or organization is a general partner (excluding any such partnership where such party, corporation or organization or any subsidiary of such party does not have a majority of the voting interest in such partnership). 

“Tax” or “Taxes” means (i) all federal, state, local or foreign taxes, charges, fees, imposts, levies
or other assessments, including all income, gross receipts, capital, sales, use, ad valorem, value added, transfer, franchise, profits, inventory, capital stock, license, withholding, payroll, employment, social security, unemployment, escheat,
excise, severance, stamp, occupation, property and estimated taxes, customs duties, fees, assessments and charges of any kind whatsoever, together with any interest, penalties, fines, additions to Tax or additional amounts (whether disputed or not)
imposed by any Taxing Authority, (ii) any Liability for the payment of any amounts of the type described in clause (i) of this sentence as a result of being a member of an affiliated, consolidated, combined, unitary, aggregate or similar
group for any taxable period, and (iii) any Liability for the payment of any amounts of the type described in clause (i) or (ii) of this sentence as a result of being a transferee of or successor to any Person or as a result of any
express or implied obligation to assume such Taxes or to indemnify any other Person or otherwise by operation of law. 
 “Tax
Return” means any return, report, information statement, estimate or claim for refund with respect to any Tax (including any elections, declarations, schedules, statements or attachments thereto, and any amendment thereof), and, where
permitted or required, affiliated, combined, consolidated, unitary, aggregate or similar returns for any group of entities. 

“Taxing Authority” shall mean the IRS or any other governmental body (whether state, local or foreign) responsible for the
administration of any Tax. 
 “Transaction” means the sale of the Shares and the related transactions as described in this
Agreement and the Related Agreements. 
 “US GAAP” means generally accepted accounting principles in the United States
applied on a consistent basis. 
 1.2 Certain Interpretations. As used in this Agreement: 

(a) References to a Schedule or an Exhibit shall mean a Schedule or an Exhibit to this Agreement unless otherwise indicated. 

  
 -5- 

 EXECUTION VERSION 
  

 (b) References to an Article or a Section shall mean to an Article or a Section of this
Agreement unless otherwise indicated. 
 (c) The words “include,” “includes” and “including” when used herein
shall be deemed in each case to be followed by the words “without limitation.” 
 (d) The words “hereof,”
“herein”, “hereby” and “hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. 

(e) The term “Dollars” or the symbol “$” shall mean United States dollars. 

(f) Unless the context otherwise requires, all references in this Agreement to the Subsidiaries of a legal entity shall be deemed to include
all direct and indirect Subsidiaries of such entity. 
 (g) The definitions contained in this Agreement are applicable to the singular as
well as the plural forms of such terms and to the masculine as well as to the feminine and neuter genders of such term. 
 (h) The headings
set forth in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. 

(i) The parties hereto agree that they have been represented by legal counsel during the negotiation and execution of this Agreement and,
therefore, waive the application of any law, regulation, holding or rule of construction providing that ambiguities in an agreement or other document shall be construed against the party drafting such agreement or document. 

(j) A reference to legislation or to a legal concept in a particular jurisdiction shall, as the context requires, be construed as a reference
to any equivalent legislation or legal concept in any other relevant jurisdiction. 
 SECTION 2 

PURCHASE AND SALE OF THE SHARES; CLOSING DELIVERIES 

2.1 Purchase and Sale of the Shares. 

(a) Angionetics hereby agrees to sell, convey, and transfer to Investor, and Investor hereby purchases from Angionetics, all legal and
beneficial right, title and interest in and to the Shares, free and clear of all Liens. 
 (b) The purchase price for the Shares is Five
dollars U.S. ($5.00) per share, for an aggregate of Three Million U.S. Dollars ($3,000,000) payable on the terms and conditions set forth below. 

(c) The sale of the Shares shall take place in two closings. Each closing will take place promptly (and in any event within five
(5) Business Days) following the satisfaction or waiver of each of the conditions to closing set forth in Section 6 below. At the first closing, Investor will purchase from Angionetics, and Angionetics will sell to Investor, 200,000
of the 

  
 -6- 

 EXECUTION VERSION 
  

 
Shares. At the second closing, Investor will purchase from Angionetics, and Investor sell to Investor, the remaining 400,000 Shares. 

2.2 Closing Deliveries. In connection with each closing, the parties will make the following deliveries: 

(a) At the first closing, (i) Angionetics shall deliver to Investor a certificate representing issuance of 200,000 the Shares; and
(ii) Investor shall deliver $1,000,000 to Angionetics by wire transfer of immediately available funds. 
 (b) At the second closing,
(i) Angionetics shall deliver to Investor a certificate representing issuance of 400,000 the Shares; and (ii) Investor shall deliver $2,000,000 to Angionetics by wire transfer of immediately available funds. 

SECTION 3 

REPRESENTATIONS AND WARRANTIES OF CARDIUM AND ANGIONETICS 

Cardium and Angionetics, jointly and severally, hereby make the representations and warranties contained in this Section 3 to
Investor; provided, however that the representations and warranties shall be qualified by the disclosure set forth in the corresponding section or subsection of the disclosure schedule delivered by Cardium and Angionetics to Investor, dated as of
the date hereof (it being understood that disclosure in any section or subsection in the Disclosure Schedule with respect to a representation or warranty shall apply to other sections or subsections in the Disclosure Schedule without repetition in
such other section or subsection to the extent that it is reasonably apparent on the face of such disclosure that the disclosure applies to such other section or subsection) (the “Disclosure Schedule”): 

3.1 Organization. 
 (a)
Cardium is a corporation duly organized, validly existing and in good standing under the laws of the state of Delaware and has full corporate power and authority to own and operate its properties and assets to carry on its business as presently
conducted or proposed to be conducted. Cardium is presently qualified to do business as a foreign corporation in each jurisdiction where the properties owned or leased by it or the operation of its business as currently conducted makes such
qualification necessary; except where the failure to be so qualified could reasonably be expected to have a material adverse effect on Cardium’s financial condition or business as presently conducted or proposed to be conducted. 

(b) Angionetics is a corporation duly organized, validly existing and in good standing under the laws of the state of Delaware and has full
corporate power and authority to own and operate its properties and assets to carry on its business as presently conducted or proposed to be conducted. Angionetics is presently qualified to do business as a foreign corporation in each jurisdiction
where the properties owned or leased by it or the operation of its business as currently conducted makes such qualification necessary; except where the failure to be so qualified could reasonably be expected to have a material adverse effect on
Angionetics’ financial condition or business as presently conducted or proposed to be conducted. 
 3.2 Authority. All corporate
action on the part of the Cardium and Angionetics necessary for the authorization, execution and delivery of this Agreement, the performance of all obligations of Angionetics and Cardium hereunder, including the sale and delivery of the 

  
 -7- 

 EXECUTION VERSION 
  

 
Shares, has been taken and no further action is required by Cardium or Angionetics, its board of directors or its stockholders in connection therewith. This Agreement constitutes a valid and
legally binding obligation of Angionetics and Cardium, enforceable in accordance with its terms except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement
of creditors’ rights generally and (b) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies. 

3.3 Subsidiaries. Angionetics does not own or control, directly or indirectly, any interest in any corporation, partnership, limited
liability company, association or other business entity. 
 3.4 No Conflicts. The execution and delivery of this Agreement by Cardium
and Angionetics, the execution and delivery of the Related Agreements by Angionetics, and each certificate and other instrument required to be executed and delivered by Cardium and Angionetics pursuant hereto and thereto, the compliance with the
provisions of this Agreement, the Related Agreements, and each certificate or other instrument required to be executed and delivered by any or each of Cardium and Angionetics pursuant hereto and thereto, the consummation of the Transaction and the
other transactions contemplated hereby and thereby, in each case, will not (a) result in any Conflict with any provision of the Organizational Documents of Cardium or Angionetics, (b) result in any Conflict with any Material Contract or
any contract or agreement or obligation to any Person with which Cardium or Angionetics had prior discussions or entered into prior agreements with regarding the issuance of equity in Angionetics and the granting of license rights that are subject
to the License Agreement, (c) result in the creation or imposition of any Lien upon any assets of any or each Cardium or Angionetics, or (d) violate in any material respect any Laws applicable to Cardium or Angionetics, or any of their
properties or assets. 
 3.5 Governmental Filings and Consents. No consent, approval, order or authorization of, or registration,
declaration, notice or filing with any Governmental Authority is required on the part of Cardium or Angionetics in connection with the execution and delivery of this Agreement or the Related Agreements or the consummation of the Transaction or any
other transactions contemplated hereby or thereby. 
 3.6 Angionetics Capital Structure. Angionetics is authorized to issue
200,000,000 shares of Common Stock and 40,000,000 shares of preferred stock, par value $0.0001 per share. There are currently 3,400,000 shares of Common Stock and zero shares of Angionetics preferred stock outstanding. Under the terms of the 2016
Equity Plan, there are reserved for issuance (i) 350,000 shares of Common Stock, plus (ii) an allotment of Common Stock equal to 10% of the Common Stock then outstanding upon the issuance of certain performance milestones described
therein. All of the outstanding shares of capital stock of Angionetics have been duly authorized and validly issued and are fully paid and non-assessable and were issued in compliance with applicable state and federal securities laws and any
applicable rights of third parties. The Shares and the Conversion Shares, when issued, will be free of any liens or encumbrances, other than any liens or encumbrances created or imposed upon Investor. Except as set forth in this
Section 3.6, there are no outstanding (i) shares of capital stock or voting securities of Angionetics, or (ii) options, warrants, script rights to subscribe to, calls or commitments of any character whatsoever relating to, or
securities, rights or obligations convertible into or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of capital stock or voting securities or securities convertible into or exchangeable for capital stock or
voting securities of Angionetics, or contracts, commitments, understandings or 

  
 -8- 

 EXECUTION VERSION 
  

 
arrangements by which Angionetics may become bound to issue additional shares of capital stock or voting securities, or securities or rights convertible or exchangeable into shares of capital
stock or voting securities of Angionetics. No Person has any right of first refusal, preemptive right, right of participation, right of first refusal, right of co-sale or similar right in favor of stockholders with respect to any of the Shares and
the Conversion Shares, or the issuance or sale thereof, whether pursuant to Angionetics’ certificate of incorporation or bylaws, applicable law, contract or otherwise. 

3.7 Financial Statements. Cardium has previously made available to Investor the following financial statements for Cardium and
Angionetics, respectively (collectively, the “Financial Statements”): (i) the unaudited consolidated balance sheet of Cardium and the unaudited balance sheet of Angionetics as of December 31, 2014 and December 31,
2015 and the consolidated statements of income, changes in stockholders’ equity and cash flow of Cardium and the statements of income, changes in stockholders’ equity and cash flow of Angionetics for the twelve (12) month period ended
December 31, 2014 and 2015, and (ii) the unaudited consolidated balance sheet of Cardium and the unaudited balance sheet of Angionetics as of March 31, 2016, (the “Interim Balance Sheet”) and consolidated statements
of income, changes in stockholders’ equity and cash flow of Cardium and statements of income, changes in stockholders’ equity and cash flow of Angionetics as of and for the two month period ended March 31, 2016. The Financial
Statements (A) are derived from and are prepared in accordance with Angionetics’ and Cardium’ books and records, and (B) are correct in all material respects and fairly present the financial condition of Angionetics and Cardium
at the dates therein indicated and the results of operations and cash flows of Angionetics and Cardium for the periods therein specified (subject, to normal recurring year-end audit adjustments, none of which individually or in the aggregate will be
material). 
 3.8 Absence of Changes. From the date of the Interim Balance Sheet to the date hereof, (i) each of Angionetics and
Cardium has operated its business in the ordinary course of business, consistent with past practice, (ii) no event or events have occurred that would, in each case or in the aggregate, be material to either Angionetics or Cardium, and
(iii) without limiting the generality of the foregoing, neither Angionetics nor Cardium has: 
 (a) increased any compensation or
benefits or paid any bonus, or granted any increase in severance or termination pay, in each case, for any individual or otherwise materially changed any of the terms of employment or service for any of its Employees; 

(b) entered into any loan or advanced any money or other property with any other Person; 

(c) incurred any Indebtedness other than trade accounts payable incurred in the ordinary course consistent with past practice; 

(d) mortgaged, pledged or subjected to any Lien, any of its properties or assets, tangible or intangible; 

(e) acquired or disposed of any assets or properties having a value in excess of $20,000 (singly or in the aggregate) other than in the
ordinary course consistent with past practice; 
 (f) forgiven or canceled any debts or claims other than in the ordinary course consistent
with past practice, or waived any rights, having a value in excess of $20,000; 

  
 -9- 

 EXECUTION VERSION 
  

 (g) incurred a capital expenditure or made a commitment exceeding $20,000; 

(h) made or changed any material election in respect of Taxes, adopted or changed any accounting method in respect of Taxes, agreed to or
settled any claim or assessment in respect of Taxes, or extended or waived any of the limitation periods applicable to any claim or assessment in respect of Taxes; 

(i) sold, assigned or disposed of, or suffered any Lien placed upon, any Company Intellectual Property; 

(j) engaged in any transaction involving real property; 

(k) incurred any damage, destruction or loss any material property or material assets, whether or not covered by insurance; 

(l) received notice of termination by a third party with respect to any Material Contract; 

(m) declared, set aside, paid or made other distribution in respect of any of its capital stock, or any direct or indirect redemption,
purchase or other acquisition of any of such stock by it; or 
 (n) entered into any agreement, commitment or obligation to do any of the
foregoing. 
 3.9 Taxes. Each of Cardium and Angionetics (or Cardium on behalf of Angionetics) has (a) timely filed all federal,
state, local and foreign franchise, income, sales, gross receipts and all other Tax Returns which are required to be filed by it and which were not delinquent prior to the date hereof, and (b) paid within the time and in the manner prescribed
by law or established reasonable reserves for the payment of all taxes, levies, assessments, fees, penalties, interest and other governmental charges accrued or payable for all periods ending on or prior to the date hereof. The Tax Returns are
complete and accurate in all material respects, and no Tax assessment or deficiency which has not been paid or for which an adequate reserve has not been set aside, has been made or proposed against Cardium or Angionetics (or Cardium on behalf of
Angionetics). None of the Tax Returns are now being examined or audited nor, to the Knowledge of Cardium and to the Knowledge of Angionetics, is there indication of intent by a Government Authority to examine or audit any Tax Return, and no consents
waiving or extending any applicable statues of limitations for the Tax Returns, or any taxes required to be paid thereunder, have been filed. 

3.10 Litigation. There is no Action pending, or to the Knowledge of Cardium and Angionetics, threatened against Cardium or Angionetics,
any of their respective properties or assets, or the Transaction or the other transactions contemplated hereby. Neither Cardium nor Angionetics is subject to, or in default with respect to, any order, writ, injunction or decree of any Governmental
Authority known to or served upon such entity. There is no Action by Cardium or Angionetics, pending or threatened against any other Person. 

3.11 Title to Assets: Property. 

(a) Each of Angionetics and Cardium has good and valid title to, or a valid leasehold interest in, all and tangible personal property and
other assets reflected in the 

  
 -10- 

 EXECUTION VERSION 
  

 
Financial Statements or acquired after the date of the Interim Balance Sheet, other than properties and assets sold or otherwise disposed of in the ordinary course. All such properties and assets
(including leasehold interests) are free and clear of Liens except for the following: (i) Liens for Taxes not yet due and payable or being contested in good faith by appropriate procedures; (ii) mechanics, carriers’, workmen’s,
repairmen’s or other like liens arising or incurred in the ordinary course of business; (iii) Liens arising under original purchase price conditional sales contracts and equipment leases with third parties entered into in the ordinary
course of business; or other imperfections of title or Liens, if any, that have not had, and would not reasonably be expected to have a material adverse effect on the financial position, or the conduct or operation of the Business as currently
conducted. 
 (b) Neither Angionetics nor Cardium owns any real property. Cardium or Angionetics has provided to Investor copies of the
Intercompany Agreements pursuant to which Angionetics has a license to use certain real property leased by Cardium. Angionetics does not currently own, nor has it ever owned, occupied or used, nor does it have any estate, interest or right in any
real property nor does it have any liability (whether actual contingent or prospective) or obligation in respect of any real property other than the license contained in the Intercompany Agreements. 

3.12 Contracts. Cardium or Angionetics has made available to Investor a true and correct copy of each of the following Contracts to
which any Angionetics is a party or by which any of Angionetics’ assets or properties, are bound as of the date hereof: 
 (a) any
Contract or series of related Contracts pursuant to which Angionetics is a party to or by which it is bound that involves (i) obligations of, or payments by Angionetics in excess of $20,000 other than in the ordinary course of Angionetics’
business, or (ii) the license of any patent, copyright, trade secret or other proprietary right to or from Angionetics, or (iii) the granting of any rights affecting the development, manufacture, licensing, marketing, sale or distribution
of Angionetics’ products or services or (iv) indemnification by Angionetics with respect to infringements of proprietary rights; 

(b) any Contract to grant any severance or other termination pay or benefits or any compromise or settlement agreement relating to the waiver
or settlement of any other employee rights or claims, in any case where such Contract has continuing financial obligations or effects, including stock options; 

(c) any Contract that Angionetics may not terminate in its discretion, with ninety (90) or fewer days’ notice, in each case without
Liability or other further material obligations, other than (i) nondisclosure or confidentiality agreements, (ii) nondisclosure or confidentiality provisions in Contracts entered into in the ordinary course of business and
(iii) Contracts with customers entered into in the ordinary course of business. 
 (d) any distributor, reseller, revenue sharing,
sales representative or similar Contract; 
 (e) any Contract (i) limiting the freedom of a Angionetics to engage or participate, or
compete with any other Person, in any line of business, market or geographic area, or to make use of any Intellectual Property, (ii) under which the Angionetics grants most favored customer pricing, exclusive sales, distribution, marketing or
other exclusive rights, rights of refusal, rights of first negotiation or similar rights and/or terms to any Person, or (iii) otherwise limiting the right of a Angionetics to (A) sell, distribute or manufacture any products, services, or

  
 -11- 

 EXECUTION VERSION 
  

 
Technology; (B) purchase or otherwise obtain any services or any software or other Technology, or (C) grant reseller rights to third parties; 

(f) any Contract restricting the ability of Angionetics or any of its respective Employees to hire or solicit potential Employees; 

(g) all Contracts pursuant to which Angionetics has agreed to any restriction on the right to use or enforce any Technology or Intellectual
Property; 
 (h) all Contracts pursuant to which Angionetics has agreed to transfer or sell rights in or with respect to any Technology or
Intellectual Property, other than licenses in the ordinary course of business; 
 (i) any Contract providing for the development of any
Technology, independently or jointly, by or for Angionetics, including any invention assignment or similar Contract between Angionetics and an Employee; 

(j) any Contract evidencing Indebtedness to any Person, or any agreement of guaranty, indemnification or other similar commitment with respect
to the obligations or Liabilities of any other Person; 
 (k) any Contract for the past, present or future sale or transfer of any material
portion of the assets or business of Angionetics; 
 (l) any Contract for the acquisition of the business or share capital of another
Person; 
 (m) any Contract, including any letter of intent, memorandum of understanding or other similar document in the past twelve months
(i) with any representative of any corporation or corporations regarding the merger of Angionetics with or into any such corporation or corporations, (ii) with any representative of any corporation, partnership, association or other
business entity or any individual regarding the sale, conveyance or disposition of all or substantially all of the assets of Angionetics or a transaction or series of related transactions in which more than fifty percent (50%) of the voting
power of Angionetics would be disposed of, or (iii) regarding any other form of liquidation, dissolution or winding up of Angionetics. 

(n) any Contract relating to the formation, creation, operation, management, or control of a joint venture, partnership, or other similar
arrangement with one or more Persons; 
 (o) any referral, affiliate marketing, joint marketing, or similar Contract; 

(p) any Contract or plan for which any benefits will be increased, calculated or accelerated, by the occurrence the Transaction (either alone
or upon the occurrence of additional or subsequent events); 
 (q) any Contracts between Angionetics and any of its Affiliates
(collectively, the “Intercompany Agreements”); or 
 (r) any settlement agreement. 

  
 -12- 

 EXECUTION VERSION 
  

 Each of the Contracts required to be made available to Investor under this Section (each, a “Material
Contract”) is a valid and binding agreement of Angionetics and Cardium, and is in full force and effect in accordance with its terms. Angionetics is not in default or material breach under the terms of any Material Contract, nor will the
consummation of the Transaction or any other transactions contemplated by this Agreement give rise to any such default or material breach. Cardium is not in default or material breach under the terms of any Material Contract, nor will the
consummation of the Transaction or any other transactions contemplated by this Agreement give rise to any such default or material breach. To the Knowledge of Cardium and to the Knowledge of Angionetics, no other party to any Material Contract is in
material default or breach of such Material Contract. 
 3.13 Intellectual Property. 

(a) Angionetics owns a valid right, title, interest or license in and to the Intellectual Property necessary or material for the operation of
its Business as currently conducted. The Disclosure Schedule contains a complete list of the following Intellectual Property of Angionetics: (i) trademarks and service marks, including all applications and registrations; (ii) copyrights,
including all applications and registrations related to the foregoing; (iii) patents and patent applications; and (iv) internet domain name registrations. 

(b) To the Knowledge of Cardium and to the Knowledge of Angionetics, all such Intellectual Property rights are enforceable and there is no
existing infringement by another Person of any of the Intellectual Property rights. 
 (c) To the Knowledge of Cardium and to the Knowledge
of Angionetics, neither Cardium nor Angionetics has violated or infringed upon the Intellectual Property rights of any other Person. There are no claims pending or, to the Knowledge of Cardium and to the Knowledge of Angionetics, threatened against
Cardium or Angionetics regarding any claim or infringement of any Intellectual Property belonging to any other Person and Cardium has not received any notice (written or otherwise) of any claim of any such infringement. 

(d) Neither Angionetic nor Cardium have entered into any license, assignment, option or transfer of any of the Intellectual Property necessary
or material to the operation of the Business with any third party, other than agreements with its own employees or consultants, standard end-user license agreements, support/maintenance agreements and agreements entered in the ordinary course of
Angionetic’s Business. 
 (e) Each employee of Angionetics or Cardium has executed a confidential information and invention assignment
agreement, in substantially the form delivered to Investor. Each consultant to Angionetics or Cardium that has had access to the Intellectual Property has entered into an agreement containing appropriate confidentiality and invention assignment
provisions. To the Knowledge of Cardium and to the Knowledge of Angionetics, no officer, employee or consultant of Cardium or Angionetics is in violation of such confidential information and invention assignment agreement or any prior employee
contract or proprietary information agreement with any other corporation or third party. 
 3.14 Personnel. 

(a) Angionetics is in compliance in all material respects with all Laws, contractual terms and terms imposed by collective agreement, staff
handbook, company policy, custom and practice and any codes of conduct and practice (or made by anybody with functions 

  
 -13- 

 EXECUTION VERSION 
  

 
or powers in relation to employees) respecting employment or engagement, as the case may be, of any Employee. Angionetics does not have any Liability with respect to any misclassification of:
(i) any Employee as an independent contractor rather than as an employee, (ii) any Employee seconded from or to, or provided by another employer, or (c) any Employee currently or formerly classified as exempt from overtime wages. 

(b) Angionetics has withheld all amounts required by applicable Laws or by Contract to be withheld from the wages, salaries, and other
payments to Employees; and is not liable for any arrears of wages, compensation, Taxes, penalties or other sums for failure to comply with any of the foregoing. Angionetics has paid in full to all Employees all wages, salaries, commissions, bonuses,
benefits and other compensation due to be paid to or on behalf of such Employees, except for such amounts as are reflected on the Interim Balance Sheet or have been accrued since the date of the Interim Balance Sheet in the ordinary course
consistent with past practice. 
 (c) Angionetics is not liable for any material payment to any trust or other fund or to any Governmental
Authority, with respect to unemployment compensation benefits, social security or other benefits or obligations for Employees (other than routine payments to be made in the normal course of business and consistent with past practice). There are no
situations ongoing, pending or, to the Knowledge of Cardium, threatened, between Angionetics and its Employees or other service providers, which could result in or has or has threatened to result in any Action before any Governmental Authority, or
any dispute, disciplinary and/or grievance investigation or procedure (including the consummation of the Transaction). 
 3.15 Employee
Benefit Plans. 
 (a) Employee Plans. Cardium has made available to Investor a list of each material Employee Plan. 

(b) Employee Plan Compliance. Angionetics and Cardium have each performed all obligations required to be performed by it under,
is not in default or violation of each Employee Plan, and each Employee Plan has been established and maintained in accordance with its terms and in compliance with all applicable Laws (including ERISA and the Code). There are no Actions pending or,
to the Knowledge of Cardium, threatened against any Employee Plan or against the assets of any Employee Plan. No Employee Plan has unfunded Liabilities. There are no audits, inquiries or proceedings pending or, to the Knowledge of Cardium,
threatened by any other Governmental Authority with respect to any Employee Plan. 
 (c) No Pension Plan or Self-Insured Plan.
Neither Cardium nor Angionetics has ever maintained, established, sponsored, participated in, or contributed to, any pension or retirement benefit plan for any Person. Neither Cardium nor Angionetics has ever maintained, established, sponsored,
participated in or contributed to any self-insured plan that provides benefits to any Person. 
 (d) No Post-Employment
Obligations. No Employee Plan provides, or reflects or represents any Liability to provide post-termination or retiree life insurance, or health benefits to any Person for any reason, except as may be required by applicable Law, and
Angionetics has not ever represented, promised or contracted (whether in oral or written form) to any Employee (either individually or to Employees as a group) or any other Person that such Employee(s) or other Person would be provided with life
insurance, health benefits after termination of employment, except to the extent required by applicable statute. 

  
 -14- 

 EXECUTION VERSION 
  

 (e) Section 280G; Compensation Deduction. Neither the execution of this
Agreement nor the consummation of the transactions contemplated hereby will result in “excess parachute payments” within the meaning of Section 280G(b) of the Code. 

3.16 Compliance with Laws; Permits. 

(a) Angionetics has conducted the Business in compliance with all applicable laws, statutes, ordinances, rules, regulations, orders and other
requirements of all national governmental authorities, and of all territories, states, municipalities and other political subdivisions and agencies thereof, having jurisdiction over it, except for violations that, individually or in the aggregate,
would not have or could not reasonably be expected to have a material adverse effect on the financial position, conduct or operation of the Business as presently conducted or proposed to be conducted. Neither Cardium nor Angionetics has received any
written notices of violation with respect to any Law in connection with the conduct, ownership or operation of the Business. To the Knowledge of Cardium and to the Knowledge of Angionetics, Angionetics is not under investigation with respect to, has
not been threatened to be charged with, nor has been given notice of, any violation of any Law by any Governmental Authority. 
 (b)
Angionetics possesses all material Permits necessary for the present conduct of its Business. Each of such Permits is in full force and effect, and there are no pending or, to the Knowledge of Cardium and to the Knowledge of Angionetics, threatened
proceedings challenging the validity of, or seeking to revoke or discontinue, any Permit. 
 3.17 Certain Relationships and Related
Transactions. 
 (a) None of the officers or directors of Cardium or Angionetics and, to the Knowledge of Cardium and to the Knowledge
of Angionetics, none of the employees of Cardium or Angionetics, has any direct or indirect ownership, participation, royalty or other interest in, or is an officer, director, employee of or consultant or contractor for any firm, partnership, entity
or corporation that competes with, or does business with, or has any contractual arrangement with Angionetics (except with respect to any interest in less than 1% of the stock of any corporation whose stock is publicly traded). 

(b) To the Knowledge of Cardium and to the Knowledge of Angionetics, none of the Related Parties or their immediate family members has any
interest in any property, real or personal, tangible or intangible (including any Intellectual Property) that is used in, or that relates to, the Business, except for the Intercompany Agreements and rights of shareholders under applicable Laws or
Intellectual Property that cannot be assigned as a matter of law. 
 (c) Angionetics does not have any obligations to Taxus Shanxi
Pharmaceuticals Co., Ltd or to Shenzhen Qianhai Taxus Industry Capital Management Co., Ltd, or to any of their Affiliates (collectively “Taxus Shanxi”), including but not limited to rights to acquire any equity of or license rights from
Angionetics or from Cardium related to Angionetics. The Related Agreements have been approved unanimously by the Board of Cardium, including by the director affiliated with and representing Taxus Shanxi. 

3.18 Insurance. Cardium has made available to Investor a list as of the date hereof of all insurance policies maintained by or on
behalf of Cardium and each of its Subsidiaries, including Angionetics. Such policies are in full force and effect and will continue in full force and 

  
 -15- 

 EXECUTION VERSION 
  

 
effect notwithstanding the sale and purchase of the Shares, and Cardium and its Subsidiaries have complied in all material respects with the provisions of such policies. 

3.19 Obligations of Management. Each officer and key employee of Angionetics is currently devoting substantially all of his or her
business time to the conduct of the business of Agionetics. Neither Cardium nor Angionetics is aware that any officer or key employee of Angionetics is planning to work less than full time at Angionetics in the future. No officer or key employee is
currently working or, to the Knowledge of Cardium or to the Knowledge of Angionetics, plans to work for a competitive enterprise, whether or not such officer or key employee is or will be compensated by such enterprise. 

3.20 Registration and Voting Rights. Except as set forth in Investors Rights Agreement, Angionetics is presently not under any
obligation and has not granted any rights to register under the Securities Act any of its presently outstanding securities or any of its securities that may hereafter be issued. Cardium has not entered into any agreements with respect to the voting
of capital shares of Angionetics. 
 3.21 Disclosure. To the Knowledge of Cardium and to the Knowledge of Angionetics, neither the
Agreement, the Related Agreements nor any other documents or certificates delivered in connection herewith, when taken as a whole, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
contained herein or therein not misleading in light of the circumstances under which they were made. 
 3.22 Brokers and Finders.
Neither Cardium nor Angionetics is a party to a Contract with any investment banker, broker, advisor or similar party, or any accountant, legal counsel or other Person retained by Cardium or Angionetics, in connection with this Agreement and the
transactions contemplated hereby. 
 3.23 No “Bad Actor” Disqualification. Each of Angionetics and Cardium has exercised
reasonable care, in accordance with SEC rules and guidance, to determine whether any Covered Person (as defined in Rule 506(d)(1) under the Securities Act) is subject to any of the “bad actor” disqualifications described in Rule
506(d)(1)(i) through (viii) under the Securities Act (“Disqualification Events”). To Angionetics’ knowledge and to Cardium’s Knowledge, no Covered Person is subject to a Disqualification Event, except for a
Disqualification Event covered by Rule 506(d)(2) or (d)(3) under the Securities Act. Each of Angionetics and Cardium has complied, to the extent applicable, with any disclosure obligations under Rule 506(e) under the Securities Act. 

SECTION 4 

REPRESENTATIONS AND WARRANTIES 

BY INVESTOR 
 Investor
hereby makes the representations and warranties contained in this Section 4 to Cardium and Angionetics: 
 4.1
Organization. Investor is a Hong Kong limited liability companyduly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation. 

4.2 Authority. Investor has all necessary corporate power and authority to execute and deliver this Agreement, the Related Agreements
and each certificate and other instrument required hereby to be executed and delivered by Investor pursuant hereto and to perform its 

  
 -16- 

 EXECUTION VERSION 
  

 
respective obligations hereunder and thereunder and to complete the Transaction and the other transactions contemplated hereby and thereby. The execution, delivery and performance by Investor of
this Agreement, the Related Agreements, and each certificate and other instrument required to be executed and delivered by Investor pursuant hereto and the consummation by Investor of the Transaction and the other transactions contemplated hereby
and thereby have been duly and validly authorized by all necessary corporate action on the part of Investor. Each of this Agreement, the Related Agreements, and each certificate and other instrument required to be executed and delivered by Investor
pursuant hereto has been duly and validly executed and delivered by Investor and will constitute a legal, valid and binding obligation of Investor, enforceable against it in accordance with its terms, subject to bankruptcy, insolvency,
reorganization or similar laws of general application affecting the rights and remedies of creditors, and to general equity principles. 

4.3 No Conflicts. The execution and delivery of this Agreement, the Related Agreements, and each certificate and other instrument
required to be executed and delivered by Investor pursuant hereto, the compliance with the provisions of this Agreement, the Related Agreements, and each certificate or other instrument required to be executed and delivered by Investor pursuant
hereto, the consummation of the Transaction and the other transactions contemplated hereby and thereby, in each case, will not (a) result in any Conflict with any provision of Investor Organizational Documents, (b) result in any Conflict
with any material Contract to which Investor is a party, (c) result in the creation or imposition of any Lien upon any assets of Investor or its Subsidiaries, or (d) violate in any material respect any Laws applicable to Investor or its
Subsidiaries or any of their respective properties or assets. 
 4.4 Governmental Filings and Consents. No consent, approval, order
or authorization of, or registration, declaration, notice or filing with any Governmental Authority is required on the part of Investor in connection with the execution and delivery of this Agreement, the Related Agreements or the consummation of
the Transaction or any other transactions contemplated hereby or thereby. 
 4.5 No Registration. The Shares and the Conversion
Shares have not been, and will not be, registered under the Securities Act by reason of a specific exemption from the registration provisions of the Securities Act, the availability of which depends upon, among other things, the bona fide nature of
the investment intent and the accuracy of Investor’s representations as expressed herein or otherwise made pursuant hereto. 
 4.6
Investment Intent. Investor is acquiring the Shares for investment for its own account not as a nominee or agent, and not with the view to, or for resale in connection with, any distribution thereof. Investor has no present intention of
selling, granting any participation in, or otherwise distributing the same in violation of the Securities Act. Investor does not have any contract, undertaking, agreement or arrangement with any person or entity to sell, transfer or grant
participation to such person or entity or to any third person or entity with respect to the Shares. 
 4.7 Investment Experience.
Investor has substantial experience in evaluating and investing in private placement transactions of securities in companies similar to Angionetics. Investor has sufficient knowledge and experience in financial and business matters such that
Investor is capable of evaluating the merits and risks of its investment in Angionetics and can protect its own interests in connection with the evaluation of the Transaction. 

  
 -17- 

 EXECUTION VERSION 
  

 4.8 Speculative Nature of Investment. Investor understands and acknowledges that
Angionetics has a limited financial and operating history and that an investment in Angionetics is highly speculative and involves substantial risks. Investor can bear the economic risk of the investment and is able, without impairing
Investor’s financial condition, to hold the Shares for an indefinite period of time and to suffer a complete loss of the investment. 

4.9 Access to Information. Investor has had an opportunity to ask questions of, and receive answers from, the officers of Cardium and
Angionetics concerning this Agreement, the exhibits and schedules attached hereto and thereto and the Transaction contemplated by this Agreement, as well as Angionetics’ business, management and financial affairs, which questions were answered
to its satisfaction. Investor believes that it has received all the information Investor considers necessary or appropriate for deciding whether to acquire the Shares. Investor is relying solely on its own counsel and not on any statements or
representations of Cardium, Angionetics or their Representatives for legal advice with respect to this investment or the Transaction contemplated by this Agreement other than the representations and warranties of Cardium and Angionetics in this
Agreement. 
 4.10 Securities Law Compliance. Investor is satisfied as to the full observance of the Laws of Investor’s
jurisdiction in connection with any invitation to purchase the Shares or any use of the agreements, including (i) the legal requirements within Investor’s jurisdiction for the purchase of the Shares, (ii) any foreign exchange
restrictions applicable to such purchase, (iii) any governmental or other consents that may need to be obtained and (iv) the income Tax and other Tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale or
transfer of the Shares. Investor’s acquisition and continued legal and beneficial ownership of the Shares will not violate any applicable securities or other Laws of Investor’s jurisdiction. 

4.11 Brokers and Finders. Investor is not a party to a Contract with any investment banker, broker, advisor or similar party, or any
accountant, legal counsel or other Person retained by Investor, in connection with this Agreement and the transactions contemplated hereby. 

SECTION 5 

ADDITIONAL AGREEMENTS 
 5.1
Right of First Refusal 
 (a) Cardium hereby grants Investor a right of first refusal to purchase any shares of Angionetics capital
stock held by Cardium, pursuant to the terms of this Section 5.1. Before Cardium or any of its Affiliates may transfer any shares of Common Stock or other capital stock in Angionetics to an unaffiliated third party, Cardium shall first
deliver to the Investor a written notice (the “Transfer Notice”) stating: (i) Cardium’s bona fide intention to transfer such shares; (ii) the name of each proposed purchaser or other transferee (each, a
“Proposed Transferee”); (iii) the type and aggregate number of securities proposed to be transferred to each Proposed Transferee (the “Offered Shares”); (iv) the bona fide cash price or, in reasonable
detail, other consideration for which Cardium proposes to transfer the Offered Shares (the “Offered Price”); and (v) whether any Proposed Transferee or any of its directors, executive officers, other officers that may serve as
a director or officer of any company in which it invests, general partners or managing members or any person that would be deemed a beneficial owner of the Offered Shares (in accordance with Rule 506(d) of the Securities Act) is subject to any Bad
Actor Disqualification (except for Bad Actor Disqualifications covered by Rule 

  
 -18- 

 EXECUTION VERSION 
  

 
506(d)(2)(ii) or (iii) or (d)(3) under the Securities Act and disclosed, reasonably in advance of the transfer, in writing in reasonable detail to the Investor). 

(b) For a period of twenty (20) days (the “Exercise Period”) after the date on which the Transfer Notice is delivered to
the Investor, the Investor shall have the right to purchase all but not less than all of the Offered Shares on the terms and conditions set forth in this Section 5.1 (the “Right of First Refusal”). In order to exercise
its Right of First Refusal, the Investor must deliver written notice to Cardium within the Exercise Period. 
 (c) The purchase price for
the Offer Shares will be the Offered Price, and if the Offered Price includes consideration other than cash, the cash equivalent value of the non-cash consideration will be determined by the Board of Directors of Angionetics, including the Series A
Director (as defined in Angionetics’ Certificate of Designation of the Series A Preferred Stock), in good faith, or by a third party valuation firm selected by the Board of Directors of Angionetics, including the Series A Director. 

(d) Subject to compliance with applicable state and federal securities laws, the Investor exercising its Right of First Refusal shall effect
the purchase of all but not less than all of the Offered Shares, including the payment of the purchase price, within twenty (20) days after the expiration of the Exercise Period (the “Right of First Refusal Closing”). Payment
of the purchase price will be made, at the option of the Investor, (i) in cash (by check), (ii) by wire transfer, (iii) by cancellation of all or a portion of any outstanding indebtedness of Cardium to the Investor, as the case may
be, or (iv) by any combination of the foregoing. At such Right of First Refusal Closing, Cardium shall deliver to the Investor one or more certificates, properly endorsed for transfer, representing such Offered Shares so purchased. 

(e) The Right of First Refusal shall expire upon the earlier of (i) Angionetic’s initial Qualified Public Offering (as defined in
the Certificate of Designation) or (ii) if the Second Closing does not occur by the termination date in Section 7.1(b)(4) of this Agreement. 

5.2 Tag-along Rights. 

(a) If at any time prior to the consummation of a Qualified Public Offering, Cardium proposes to sell Common Stock of the Company representing
more than 20% of the outstanding Common Stock to an un-affiliated third party (the “Proposed Transferee”) the Investor shall be permitted to participate in such sale (a “Tag-along Sale”) on the terms and conditions
set forth in this Section 5.2, if Investor has not exercised its rights of first refusal in Section 5.1. 
 (b)
Prior to the consummation of the sale described in Section 5.2 Cardium shall deliver to the Investor a written notice (a “Sale Notice”) of the proposed sale no more than 5 Business Days after the execution and delivery by all
the parties thereto of the definitive agreement entered into with respect to the Tag-along Sale and, in any event, no later than 10 Business Days prior to the closing date of the Tag-along Sale. The Sale Notice shall make reference to
Investor’s rights hereunder and shall describe in reasonable detail: (i) the number of shares of Common Stock to be sold by Cardium; (ii) the name of the Proposed Transferee; (iii) the per share purchase price and the other
material terms and conditions of the sale, including a description of any non-cash consideration in sufficient detail to permit the valuation thereof; (iv) the proposed date, time and location of the closing of the sale; and (v) a copy of
any form of agreement proposed to be executed in connection therewith. 

  
 -19- 

 EXECUTION VERSION 
  

 (c) Investor shall exercise its right to participate in a Tag-Along Sale by delivering to
Cardium a written notice (a “Tag-along Notice”) stating its election to do so and specifying the number of shares of Common Stock to be sold by it no later than five Business Days after receipt of the Sale Notice (the
“Tag-along Period”). Investor shall have the right to sell in a sale subject to Section 5.2 the number of shares of Common Stock equal to the product obtained by multiplying (i) the number of shares of Common Stock
held by Investor and its affiliates by (ii) a fraction (A) the numerator of which is equal to the number of shares of Common Stock Cardium proposes to sell or transfer to the Proposed Transferee and (B) denominator of which is equal
to the number of shares of Common Stock then owned by Cardium. If Investor does not deliver a Tag-along Notice, Investor shall be deemed to have waived its right to participate in such sale, and Cardium shall thereafter be free to sell to the
Proposed Transferee its shares of Common Stock at a per share price that is no greater than the per share price set forth in the Sale Notice and on other same terms and conditions which are not materially more favorable to Cardium than those set
forth in the Sale Notice, without any further obligation to Investor. Cardium shall have 20 Business Days following the expiration of the Tag-along Period in which to sell the shares of Common Stock described in the Sale Notice, on terms not more
favorable than those set forth in the Sale Notice. If at the end of such period Cardium has not completed such sale, Cardium may not then effect a sale of Common Stock subject to this Section 5.1 and 5.2 without again fully complying
with the provisions of this Section 5.1 and 5.2. 
 (d) Investor shall take all actions as may be reasonably necessary to
consummate the Tag-along Sale, including, without limitation, entering into agreements and delivering certificates and instruments, in each case, consistent with the agreements being entered into and the certificates being delivered by Cardium.
Investor shall be entitled to receive the same consideration per share as Cardium, and shall make or provide the same representations, warranties, covenants, indemnities and agreements as Cardium makes or provides in connection with the Tag-along
Sale (except that in the case of representations, warranties, covenants, indemnities and agreements pertaining specifically to Cardium, Investor shall make the comparable representations, warranties, covenants, indemnities and agreements pertaining
specifically to itself); provided, that all representations, warranties, covenants and indemnities shall be made by Cardium and Investor severally and not jointly and any indemnification obligation in respect of breaches of representations
and warranties that do not relate Investor shall be in an amount not to exceed the aggregate proceeds received by Investor in connection with any Tag-along Sale. 

(e) This Section 5.1 and 5.2 shall not apply to (i) sales of Common Stock to any employee of Cardium, or (ii) sales in a
distribution to the public (whether pursuant to a registered public offering, Rule 144 or otherwise). 
 5.3 Survival of Representations
and Warranties. The representations and warranties contained in this Agreement, or any instrument or certificate delivered pursuant to this Agreement, shall survive the closing of the Transaction contemplated hereby for a period of one
(1) year and no party shall have any recourse with respect to any breach of any such representation or warranty for any Action initiated after that time, in each case, except that: (i) each Fundamental Representation shall survive the
closing and shall terminate on the date that is thirty (30) days following the expiration of the longest statute of limitations applicable to such Fundamental Representation; and (ii) each representation and warranty shall survive
indefinitely with respect to any claim based upon, arising out of or related to fraud, willful breach or intentional misrepresentation. None of the covenants or other agreements contained in this Agreement shall survive the closing other than those
which by their terms contemplate 

  
 -20- 

 EXECUTION VERSION 
  

 
performance after the date hereof, and each such surviving covenant and agreement shall survive the closing of the Transaction for the period contemplated by its terms. Notwithstanding the
foregoing, any claims asserted in good faith with reasonable specificity (to the extent known at such time) and in writing by notice from the non-breaching party to the breaching party prior to the expiration date of the applicable survival period
shall not thereafter be barred by the expiration of such survival period and such claims shall survive until finally resolved. 
 5.4
Indemnification. 
 (a) Indemnification by Cardium and Angionetics. Cardium and Angioetics, jointly and severally,
shall indemnify and hold harmless Investor for any Damages resulting from, arising out or, or relating to (i) any inaccuracy in or breach of any of the representations or warranties of Cardium and Angionetics contained in this Agreement; or
(ii) any breach or non-fulfillment of any covenant, agreement or obligation to be performed by Cardium or Angionetics pursuant to this Agreement. 

(b) Indemnification by Investor. Investor shall indemnify and hold harmless Angionetics for any Damages resulting from, arising
out or, or relating to (i)any inaccuracy in or breach of any of the representations or warranties of Investor contained in this Agreement; or (ii) any breach or non-fulfillment of any covenant, agreement or obligation to be performed by
Investor pursuant to this Agreement. 
 (c) Indemnification Procedures. Any claim by an indemnified party on account of
Damages shall be asserted by the indemnified party giving the indemnifying party prompt written notice thereof. The failure to give such prompt written notice shall not, however, relieve the indemnifying party of its indemnification obligations,
except and only to the extent that the indemnifying party forfeits rights or defenses by reason of such failure. Such notice by the indemnified party shall describe the claim in reasonable detail, shall include copies of all material written
evidence thereof and shall indicate the estimated amount, if reasonably practicable, of the Damages that has been or may be sustained by the indemnified party. The indemnifying party shall have thirty (30) days after its receipt of such notice
to respond in writing to such claim. During such thirty (30) day period, the indemnified party shall allow the indemnifying party and its professional advisors to investigate the matter or circumstance alleged to give rise to the claim, and
whether and to what extent any amount is payable in respect of the claim and the indemnified party shall assist the indemnifying party’s investigation by giving such information and assistance (including access to the indemnified party’s
premises and personnel and the right to examine and copy any accounts, documents or records) as the indemnifying party or any of its professional advisors may reasonably request. If the indemnifying party does not so respond within such thirty
(30) day period, the indemnifying party shall be deemed to have rejected such claim, in which case the indemnified party shall be free to pursue such remedies as may be available to the indemnified party on the terms and subject to the
provisions of this Agreement. 
 5.5 Certain Payments. Investor agrees that Angionetics will use up to $500,000 of the proceeds to
pay accrued legal, accounting and payroll expenses incurred by Cardium in connection with the formation and establishment of Angionetics. Amounts paid by Angionetics will be credited against the $2 million transfer payment owed by Angionetics to
Cardium upon the occurrence of an initial public offering under the terms of the Contribution Agreement between Cardium and Angionetics. 

  
 -21- 

 EXECUTION VERSION 
  

 5.6 Refund of Term Sheet Fee. Within 15 Business Days following the initial Closing
under this Agreement, Angionetics will refund to Zhang Songshanthe $250,000 fee paid in connection with the execution and delivery the Term Sheet attached hereto as Exhibit D. 

SECTION 6 
 CONDITIONS TO
CLOSING 
 6.1 Conditions to Obligations of All Parties. The obligations of each party to consummate the transactions
contemplated by this Agreement shall be subject to the fulfillment, at or prior to each Closing, of each of the following conditions: 
 (a)
No Governmental Authority shall have enacted, issued, promulgated, enforced or entered any order which is in effect and has the effect of making the transactions contemplated by this Agreement illegal, otherwise restraining or prohibiting
consummation of such transactions or causing any of the transactions contemplated hereunder to be rescinded following completion thereof. 

(b) No Action shall have been commenced against Angionetics or Investor which would prevent the Closing. 

6.2 Conditions to Obligations of Investor. The obligations of Investor to consummate the transactions contemplated by this Agreement
shall be subject to the fulfillment or Investor’s waiver, at or prior to each Closing, of each of the following conditions: 
 (a) The
representations and warranties of Angionetics and Cardium contained in this Agreement, the other Transaction Documents and any certificate or other writing delivered pursuant hereto shall be true and correct in all respects (in the case of any
representation or warranty qualified by materiality) or in all material respects (in the case of any representation or warranty not qualified by materiality) on and as of the date hereof and on and as of the Closing Date with the same effect as
though made at and as of such date (except those representations and warranties that address matters only as of a specified date, the accuracy of which shall be determined as of that specified date in all respects). 

(b) Angionetics and Cardium shall have duly performed and complied with all agreements, covenants and conditions required by this Agreement
and each of the other Transaction Documents to be performed or complied with by it prior to or on the Closing Date; provided, that, with respect to agreements, covenants and conditions that are qualified by materiality, Angionetics and
Cardium shall have performed such agreements, covenants and conditions, as so qualified, in all respects. 
 (c) The Related Agreements
shall have been executed and delivered by the parties thereto and true and complete copies thereof shall have been delivered to Investor. 

(d) The Investor shall have received a certificate, dated the Closing Date and signed by an officer of Angionetics and an officer of Cardium,
that each of the conditions set forth in Section 6.2(a) and Section 6.2(b) have been satisfied. 
 (e) The Investor shall have
received a certificate of the Secretary (or equivalent officer) of each of Angionetics and Cardium certifying that attached thereto are true and complete copies of all resolutions adopted by the board of directors of Angionetics and Cardium
authorizing the execution, delivery and performance of this Agreement and the other 

  
 -22- 

 EXECUTION VERSION 
  

 
Transaction Documents and the consummation of the transactions contemplated hereby and thereby, and that all such resolutions are in full force and effect and are all the resolutions adopted in
connection with the transactions contemplated hereby and thereby. 
 (f) Angionetics and Cardium shall have delivered to Investor a good
standing certificate from the Delaware Secretary of State as of a recent date. 
 (g) Investor shall have received an opinion of counsel for
each of Angionetics and Cardium in the form of Exhibit E. 
 (h) With respect to the second Closing only, Angionetics shall have provided
Investor with evidence of the approval the United States Food and Drug Administration granting Angionetics clearance to conduct a Phase III clinical trial of Generx® [Ad5FGF-4] in the United
States. 
 6.3 Conditions to Obligations of Angionetics. The obligations of Angionetics to consummate the transactions contemplated
by this Agreement shall be subject to the fulfillment or Angionetics’ waiver, at or prior to each Closing, of each of the following conditions: 

(a) The representations and warranties of Investor contained in this Agreement, the other Transaction Documents and any certificate or other
writing delivered pursuant hereto shall be true and correct in all respects (in the case of any representation or warranty qualified by materiality) or in all material respects (in the case of any representation or warranty not qualified by
materiality) on and as of the date hereof and on and as of the Closing Date with the same effect as though made at and as of such date (except those representations and warranties that address matters only as of a specified date, the accuracy of
which shall be determined as of that specified date in all respects). 
 (b) The Investor shall have duly performed and complied with all
agreements, covenants and conditions required by this Agreement and each of the other Transaction Documents to be performed or complied with by it prior to or on the Closing Date; provided, that, with respect to agreements, covenants
and conditions that are qualified by materiality, Investor shall have performed such agreements, covenants and conditions, as so qualified, in all respects. 

(c) The Related Agreements shall have been executed and delivered by the parties thereto and true and complete copies thereof shall have been
delivered to Angionetics. 
 (d) Angionetics shall have received a certificate, dated the Closing Date and signed by a duly authorized
officer of Investor, that each of the conditions set forth in Section 6.3(a) and 6.3(b) have been satisfied. 
 (e)
Angionetics shall have received a certificate of the Secretary (or equivalent officer) of Investor certifying that attached thereto are true and complete copies of all resolutions adopted by the board of directors of Buyer authorizing the execution,
delivery and performance of this Agreement and the other Transaction Documents and the consummation of the transactions contemplated hereby and thereby, and that all such resolutions are in full force and effect and are all the resolutions adopted
in connection with the transactions contemplated hereby and thereby. 

  
 -23- 

 EXECUTION VERSION 
  

 (f) The Investor shall have delivered to Angionetics cash in an amount equal to the purchase
price for the Shares being acquired at each Closing by wire transfer in immediately available funds, to an account or accounts designated at least two Business Days prior to the Closing Date by Angionetics in a written notice to Investor. 

SECTION 7 
 TERMINATION

 7.1 Termination. This Agreement may be terminated at any time prior to the initial Closing: 

(a) by the mutual written consent of Angionetics and Investor; 

(b) by Angionetics by written notice to Investor if: 

(1) the initial Closing has not occurred within fifteen (15) Business Days of the date of this Agreement; 

(2) Angionetics is not then in material breach of any provision of this Agreement and there has been a breach, inaccuracy in or
failure to perform any representation, warranty, covenant or agreement made by Investor pursuant to this Agreement that would give rise to the failure of any of the conditions specified in Section 6 and such breach, inaccuracy or failure has
not been cured by Investor within ten days of Investor’s receipt of written notice of such breach from Angionetics; 

(3) any of the conditions set forth in Section 6.1 or Section 6.3 shall not have been, or if it becomes
apparent that any of such conditions will not be, fulfilled by July 15, 2016, unless such failure shall be due to the failure of Angionetics to perform or comply with any of the covenants, agreements or conditions hereof to be performed or
complied with by it prior to the Closing; and 
 (4) as to Investors rights to acquire the 400,000 Shares, if the second
Closing has not occurred on or before September 30, 2016 (or such later date as Angionetics and Investor may mutually agree). 
 (c) by
Investor by written notice to Angionetics if: 
 (1) Investor is not then in material breach of any provision of this
Agreement and there has been a breach, inaccuracy in or failure to perform any representation, warranty, covenant or agreement made by Angionetics pursuant to this Agreement that would give rise to the failure of any of the conditions specified in
Section 6 and such breach, inaccuracy or failure has not been cured by Angionetics within ten days of Angionetics’ receipt of written notice of such breach from Investor; or 

(2) any of the conditions set forth in Section 6.1 or Section 6.2 shall not have been, or if it becomes
apparent that any of such conditions will not be, fulfilled by July 15, 2016, unless such failure shall be due to the failure of Investor to perform or comply with any of the covenants, agreements or conditions hereof to be performed or
complied with by it prior to the Closing. 

  
 -24- 

 EXECUTION VERSION 
  

 7.2 Effect of Termination. In the event of the termination of this Agreement prior to
the initial Closing then the Agreement shall become void and there shall be no liability on the part of any party hereto except that nothing herein shall relieve any party hereto from liability for any fraud or willful breach or any provision of
this Agreement. In the event that this Agreement is terminated after the initial Closing, but prior to the second Closing, then this Agreement shall remain in effect as to the Shares sold pursuant to the initial Closing, including but not limited to
all the provisions of Section 5, but Angionetics shall have no obligation to sell, and Investor shall have no right or obligation to purchase any additional Shares following such termination. 

SECTION 8 

MISCELLANEOUS 
 8.1
Further Assurances. Each party to this Agreement shall use commercially reasonable efforts to execute and deliver such other certificates, instruments, agreements and other documents, and do and perform such other acts and things, as may be
reasonably necessary or desirable for purposes of effecting completely the consummation of the Transaction and the other transactions contemplated hereby. 

8.2 Notices. All notices and other communications required or permitted hereunder shall be in writing and shall be sent by facsimile or
electronic mail, or otherwise delivered by hand, messenger or courier service addressed: 
 (a) if to Investor, to Flat 01A, 10/F Carnival
Commercial Building 18 Java Road, North Point, Hong Kong, to the attention of the Chief Executive Officer or at such other current address as Investor shall have furnished to Cardium and Angionetics or 

(b) if to the Cardium or Angionetics, to the attention of the Chief Executive Officer of Cardium or Angionetics at 11750 Sorrento Valley Road,
Suite 250, San Diego, CA 92121, or at such other current address as Cardium or Angionetics shall have furnished to Investors. 
 Each such notice or other
communication shall for all purposes of this Agreement be treated as effective or having been given (i) if delivered by hand, messenger or courier service, when delivered (or if sent via a nationally-recognized overnight courier service,
freight prepaid, specifying next-business-day delivery, one business day after deposit with the courier), or (ii) if sent via facsimile, upon confirmation of facsimile transfer or, (iii) if sent via electronic mail, upon confirmation of
delivery when directed to the relevant electronic mail address, if sent during normal business hours of the recipient, or if not sent during normal business hours of the recipient, then on the recipient’s next business day. 

8.3 Fees and Expenses. Each of the parties hereto shall each pay their own expenses in connection with the negotiation and execution of
this Agreement and the Transaction contemplated hereby. 
 8.4 Successors and Assigns. All covenants and agreements and other
provisions set forth in this Agreement and made by or on behalf of any of the parties hereto shall bind and inure to the benefit of the successors, heirs and permitted assigns of such party, whether or not so expressed. None of the parties may
assign or transfer any of their respective rights or obligations under this Agreement without the consent in writing of the other party; provided however that Investor may assign its rights and obligations hereunder to an Affiliate of Investor. 

  
 -25- 

 EXECUTION VERSION 
  

 8.5 Third Parties. Except as specifically set forth or referred to herein, nothing
herein expressed or implied is intended or shall be construed to confer upon or give to any Person any rights or remedies under or by reason of this Agreement or any other certificate, document, instrument or agreement executed in connection
herewith nor be relied upon other than the parties hereto and their respective permitted successors or assigns. 
 8.6 Entire
Agreement. This Agreement, including the Disclosure Schedule (and all exhibits and schedules thereto) and all Exhibits and Schedules to this Agreement, the Related Agreements and all other agreements referred to herein set forth the entire
understanding of the parties hereto relating to the subject matter hereof and thereof and supersede any prior understandings and agreements relating to the subject matter hereof and thereof (including the Term Sheet); provided, however, that the
Non-Disclosure Agreement between the parties dated January 16, 2016 shall survive the execution and delivery of this agreement and remain in full force and effect. 

8.7 Amendments. Except as expressly provided herein, neither this Agreement nor any term hereof may be amended, waived, discharged or
terminated other than by a written instrument referencing this Agreement and signed by the parties. 
 8.8 No Delays or Omissions.
Except as expressly provided herein, no delay or omission to exercise any right, power or remedy accruing to any party to this Agreement upon any breach or default of any other party under this Agreement shall impair any such right, power or remedy
of such non-defaulting party, nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be
deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of
any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party
to this Agreement, shall be cumulative and not alternative 
 8.9 Governing Law. This Agreement shall be governed in all respects by
the internal laws of the State of California as applied to agreements entered into among California residents to be performed entirely within California, without regard to principles of conflicts of law. 

8.10 Jurisdiction; Venue. With respect to any disputes arising out of or related to this Agreement, the parties consent to the
exclusive jurisdiction of, and venue in, the state courts in San Diego County in the State of California (or in the event of exclusive federal jurisdiction, the courts of the Southern District of California). 

8.11 Attorneys’ Fees. In the event that any suit or action is instituted to enforce any provision in this Agreement, the
prevailing party in such dispute shall be entitled to recover from the losing party such reasonable fees and expenses of attorneys and accountants, which shall include, without limitation, all fees, costs and expenses of appeals. 

8.12 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be enforceable against the parties
that execute such counterparts, and all of which together shall constitute one instrument. This Agreement and may be delivered by electronic mail in portable document format or other means intended to preserve the original 

  
 -26- 

 EXECUTION VERSION 
  

 
graphic content of a signature. Such execution and delivery shall be considered valid, binding and effective for all purposes. At the request of any party hereto, all parties hereto agree to
execute and deliver an original of this Agreement as well as any facsimile or other reproduction hereof. 
 (signature page follows)

  
 -27- 

 EXECUTION VERSION 
  

 IN WITNESS WHEREOF, the parties hereto have duly executed this Share Purchase Agreement as of
the day and year first above written. 
  

			
	TAXUS CARDIUM PHARMACEUTICALS GROUP, INC.
		
	By:	 	 /s/ CHRISTOPHER J. REINHARD

		 	Christopher J. Reinhard
		 	Chief Executive Officer
	
	ANGIONETICS, INC.
		
	By:	 	 /s/ CHRISTOPHER J. REINHARD

		 	Christopher J. Reinhard
		 	Chief Executive Officer
	
	PINEWORLD CAPITAL LIMITED
		
	By:	 	 /s/ YIZHOU ZHANG

	Name: Yizhuo Zhang
	Title: Head of Investment

  
 Signature Page to Share
Purchase Agreement 

 EXECUTION VERSION 
  

 EXHIBIT D 

name: ZHANG SONGSHAN
 account no.
622-029601-888 
 bank name: The Hong Kong and Shanghai Banking Corporation Limited 

Address: Head Office, 1 Queen’s Road Central, Hongkong 

Swift code: HSBCHKHHHKH 

  
 Signature Page to Share
Purchase AgreementEX-10.2

 Exhibit 10.2 

CONTRIBUTION AGREEMENT BETWEEN 

TAXUS CARDIUM PHARMACEUTICALS GROUP & ANGIONETICS INC. 

This Contribution Agreement (the “Agreement”), is made and entered into as of June 6, 2016, by and between Taxus
Cardium Pharmaceuticals Group, Inc., a Delaware corporation (“Cardium”), and Angionetics, Inc., a Delaware corporation and a wholly owned subsidiary of Cardium (“Angionetics”) with respect to the following facts:

 A. Cardium through its Cardium Therapeutics operating unit has been engaged in the development of novel gene therapies for the treatment
of cardiac microvascular insufficiency, including the development of its Generx® product candidate (the “Business”). 

B. Angionetics was established as a subsidiary of Cardium for the purpose of securing third party financing in order to conduct the Business
and continue the development of the Generx product candidate, and Cardium currently holds 3,400,000 shares (the “Shares”) of the common stock, par value $0.0001 of Angionetics (the “Common Stock”). 

C. Cardium and Angionetics desire to enter into this Agreement to (i) provide for Cardium’s contribution of the assets and
liabilities related to the Business and its Generx® product candidate to Angionetics, on the terms and subject to the conditions set forth in this Agreement
(the “Contribution”), and (ii) to provide for certain rights and restrictions related to the transfer of the Common Stock held by Cardium. 

D. Cardium and Angionetics intend that the Contribution qualify as a tax-free transaction pursuant to Section 351 of the Internal Revenue
Code of 1986, as amended. 
 E. Concurrently with the execution and delivery of this Agreement, Cardium and Angionetics are entering into a
Services Agreement of even date herewith (the “Services Agreement”) to provide for the joint use of certain assets and services for a transition period. 

NOW, THEREFORE, in consideration of the mutual covenants, terms and conditions set forth in this Agreement, and intending to be legally bound,
the parties agree as follows: 
 1. Contribution of Assets. On the terms and subject to the conditions set forth in this
Agreement, Cardium hereby contributes, transfers, assigns, conveys and delivers to Angionetics, and Angionetics does hereby acquire, accept and assume from Cardium, all of Cardium’s right, title and interest in, to and under the assets used in
the Business as described in Schedule 1 (the “Assets”) and assumes all liabilities and obligations of Cardium to the extent exclusively or primarily used in the Business or resulting from, relating to or arising out of
the Assets of whatever kind or nature (whether absolute, accrued, contingent, determined, determinable, disclosed, known or unknown, or otherwise) (the “Assumed Liabilities”) including without limitation those liabilities
described in Schedule 2. The Assets shall specifically exclude any tax assets, including NOLs. Nothing contained herein shall prevent Angionetics or its affiliates from contesting in good faith any of the Assumed Liabilities with any third-party
obligee. 
 2. Third Party Consents. To the extent that Cardium’s rights under any contract or permit constituting an Asset may
not be assigned to Angionetics without the consent of another Person which has not been obtained, this Agreement shall not constitute an agreement to assign the same if an attempted assignment would constitute a breach thereof or be unlawful,

  
 -1- 

 
and Cardium, at its expense, shall use its reasonable best efforts to obtain any such required consent(s) as promptly as possible. If any such consent shall not be obtained or if any attempted
assignment would be ineffective or would impair Angionetics’ rights under the Asset in question so that Angionetics would not in effect acquire the benefit of all such rights, Cardium, to the maximum extent permitted by law and the Asset, shall
act after the closing as Angionetics’ agent in order to obtain for it the benefits thereunder and shall cooperate, to the maximum extent permitted by law and the Asset, with Angionetics in any other reasonable arrangement designed to provide
such benefits to Angionetics. 
 3. Consideration. As consideration for the Contribution Angionetics shall pay Cardium a
$2,000,000 technology fee. The technology fee shall be recorded as an inter-company payable on the accounts of Cardium, and shall be due and payable upon the earlier of (i) Angionetics’ IPO (as defined below), (ii) Angionetics’
next equity financing that raises in excess of $20 million, or (iii) any Change of Control of Angionetics. For purposes of this Agreement, “Change of Control” shall mean (a) any sale, lease or transfer or series of sales,
leases or transfers of all or substantially all of the consolidated assets of Angionetics and any subsidiaries; (b) any sale, transfer or issuance (or series of sales, transfers or issuances) of capital stock by Angionetics or the holders of
Common Stock (or other voting stock of Angionetics) that results in the inability of the holders of Common Stock (or other voting stock of Angionetics) immediately prior to such sale, transfer or issuance to designate or elect a majority of the
board of directors (or its equivalent) of the Corporation; or (c) any merger, consolidation, recapitalization or reorganization of Angionetics with or into another person (whether or not Angionetics is the surviving corporation) that results in
the inability of the holders of Common Stock (or other voting stock of Angionetics) immediately prior to such merger, consolidation, recapitalization or reorganization to designate or elect a majority of the board of directors (or its equivalent) of
the resulting entity or its parent company. 
 4. Lock-Up Agreement. Angionetics intends to seek additional financing in order to
fund its operations, including a possible sale of shares pursuant to a registration statement filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (the
“Securities Act”). In the event that Angionetics completes a firm commitment underwritten initial public offering (an “IPO”) then, for the period commencing immediately prior to the effectiveness of the registration
statement for the IPO and expiring twelve months following the closing of the IPO (the “Lock-Up Period”), Cardium shall not, without the consent of the managing underwriter of the IPO and the board of directors of Angionetics,
directly or indirectly: (1) offer, assign, encumber, announce the intention to sell, sell, contract to sell (including any short sale), sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or
warrant to purchase, distribute to its shareholders or any other individual or entity, or otherwise transfer or dispose of, any of the Shares, or (2) enter into any swap or other agreement that transfers, in whole or in part, any of the
economic consequences of ownership of any of the Shares, whether the consideration for any such transaction described in clause (1) or (2) above is cash or otherwise. 

5. Piggyback Registration Rights. Following the Lock-Up Period, and for so long as Cardium and its Affiliates own greater than 9.9% of
the issued and outstanding Common Stock, if Angionetics proposes to register any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than: (1) a registration relating to
the sale or issuance of securities to employees of Angionetics or a subsidiary pursuant to a stock option, stock purchase, or similar employee benefit plan or (2) a registration relating to an SEC Rule 145 transaction), Angionetics shall, at
such time, promptly give Cardium notice of such registration. Upon Cardium’s request given within twenty (20) days 

  
 -2- 

 
after receipt of such notice, Angionetics shall, subject to the provisions below, cause to be registered all of the Shares Cardium has requested to be included in such registration; provided that
Cardium’s registration rights under this Section shall never be more than fifty percent (50%) of the value of all securities to be registered in such offering. Angionetics shall have the right to terminate or withdraw any registration
initiated by it before the effective date of such registration, whether or not Cardium has elected to include Shares in such registration. The inclusion of Shares in the registration shall be subject to the same terms as the other securities in such
offering. Angionetics shall pay for the expenses in connection with a piggyback registration other than any underwriter discounts and commissions, or fees of Cardium’s counsel. 

6. Restrictions Relating to Debt. If Cardium uses all or any portion of the Shares as collateral for any Indebtedness (as defined
below) of Cardium or its Affiliates, Cardium shall disclose in writing to any creditor that the Shares are subject to the restrictions on transfer contained in this Agreement. Any certificate representing the Shares shall bear restrictive legends,
substantially as follows. 
 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO
REGISTRATION OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY
APPLICABLE STATE SECURITIES LAWS. 
 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE,
INCLUDING A LOCK-UP PERIOD IN THE EVENT OF A PUBLIC OFFERING, AS SET FORTH IN A CONTRIBUTION AGREEMENT AMONG THE COMPANY AND THE ORIGINAL HOLDERS OF THESE SHARES, COPIES OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE COMPANY. 

Any creditor exercising rights or remedies with respect to the Shares shall assume all of the obligations of Cardium under this Agreement. The term
“Indebtedness” means, with respect to Cardium, (1) all obligations for borrowed money, (2) all obligations evidenced by bonds, debentures, notes or other similar instruments, or upon which interest payments are customarily
made, (3) all obligations to pay the deferred purchase price of property or services, but excluding obligations to trade creditors incurred in the ordinary course of business and not past due by more than ninety (90) days, (4) all
capital lease obligations, (5) the principal balance outstanding under any synthetic lease, tax retention operating lease, off-balance sheet loan or similar off-balance sheet financing product, (6) all obligations to purchase securities
(or other property) which arise out of or in connection with the issuance or sale of the same or substantially similar securities (or property), (7) all contingent or non-contingent obligations to reimburse any bank or other person in respect
of amounts paid under a letter of credit or similar instrument, (8) all indebtedness secured by a lien on any asset, whether or not such indebtedness is otherwise an obligation, (9) all obligations under any foreign exchange contract,

  
 -3- 

 
currency swap agreement, interest rate swap, cap or collar agreement or other similar agreement or arrangement designed to alter the risks arising from fluctuations in currency values or interest
rates, in each case whether contingent or matured, and (10) all obligations or liabilities of others guaranteed by Cardium. 
 7.
Confidentiality. Each Party agrees to hold, and to cause its respective affiliates, directors, officers, employees, agents, accountants, counsel and other advisors and representatives to hold, in strict confidence, and undertake
commercially reasonable precautions to safeguard and protect the confidentiality of, all information concerning the other party that is in its possession or furnished by the other party or its respective affiliates, directors, officers, employees,
agents, accountants, counsel and other advisors and representatives at any time pursuant to this Agreement or otherwise (“Confidential Information”). For purposes of this Agreement, information shall cease to be Confidential
Information when such information is: (1) placed in the public domain through no fault of such party, (2) lawfully acquired from other sources, which are not bound by a confidentiality obligation, or (3) independently generated
without reference to or use of any proprietary or confidential information of the other party. Neither party shall release or disclose, or permit to be released or disclosed, any the Confidential Information of the other party to any other
individual or entity, except its directors, officers, employees, agents, accountants, counsel and other advisors and representatives who need to know such Confidential Information and who are informed and advised that the Confidential Information
and subject to the obligations hereunder. Notwithstanding the foregoing, if a party either: (1) determines after consultation with counsel, in the opinion of such counsel that it is required by law to disclose any Information, or
(2) receives any demand under lawful process or from any governmental authority to disclose or provide Confidential Information of the other party, then such party shall notify the other party prior to disclosing or providing such Confidential
Information and shall cooperate at the expense of the requesting party (and to the extent legally permissible) in seeking any reasonable protective arrangements requested by such other Party. Subject to the foregoing, the party receiving such
request may thereafter furnish only that portion of the Confidential Information that is legally required, shall give notice to the other party of the Confidential Information to be disclosed as far in advance as is practical, and shall exercise
reasonable best efforts to obtain reliable assurance that the confidential nature of such Confidential Information shall be maintained. 

8. Privileged Matters. To allocate the interests of each party with respect to privileged information, Cardium and Angionetics
agree as follows: 
 (a) Cardium shall be entitled, in perpetuity, to control the assertion or waiver of all privileges in connection with
privileged information that relates solely to the business of Cardium, whether or not the privileged information is in the possession of or under the control of Cardium or Angionetics. Cardium shall also be entitled, in perpetuity, to control the
assertion or waiver of all privileges in connection with privileged information that relates solely to the subject matter of any claims for which Cardium has the responsibility to indemnify Angionetics hereunder, now pending or which may be asserted
in the future, in any investigations, administrative, civil, or criminal or other proceedings initiated against or by Cardium, whether or not the privileged information is in the possession of or under the control of Cardium or Angionetics. 

(b) Angionetics shall be entitled, in perpetuity, to control the assertion or waiver of all privileges in connection with privileged
information which relates solely to the business of Angionetics whether or not the privileged information is in the possession of or under the control of Cardium or Angionetics. Angionetics shall also be entitled, in perpetuity, to control the

  
 -4- 

 
assertion or waiver of all privileges in connection with privileged information which relates solely to the subject matter of any claims for which Angionetics has the responsibility to indemnify
Cardium hereunder, now pending or which may be asserted in the future, in any any investigations, administrative, civil, or criminal or other proceedings initiated against or by Angionetics whether or not the privileged information is in the
possession of or under the control of Cardium or Angionetics. 
 (c) Cardium and Angionetics agree that they shall have a shared privilege,
with equal right to assert or waive, subject to the restrictions of this Section with respect to all privileges not allocated pursuant to the terms of Sections 10(a) and (b). All privileges relating to any claims, proceedings, litigation, disputes
or other matters which involve both Cardium and Angionetics in respect of which Cardium and Angionetics retain any responsibility or liability under this Agreement shall be subject to a shared privilege. 

(d) In the case of information that is subject to a shared privilege, no party may waive any privilege that could be asserted under any
applicable law, without the consent of the other party, except to the extent reasonably required in connection with any litigation with third parties. Such consent shall be in writing, or shall be deemed to be granted unless written objection is
made within twenty (20) days after notice upon the other party requesting such consent. Notwithstanding the foregoing, in the event of any litigation or dispute between Cardium and Angionetics regarding the subject matter hereof, either party
may waive a privilege in which the other party has a shared privilege, without obtaining the consent of the other party, provided that any such waiver of a shared privilege shall be effective only as to the use of information with respect to the
litigation or dispute between the parties and shall not operate as a waiver of the shared privilege with respect to third parties. 
 (e) If
a dispute arises between the parties regarding the subject matter hereof whether a privilege should be waived to protect or advance the interest of either party, each party shall negotiate in good faith, shall endeavor to minimize any prejudice to
the rights of the other party, and shall not unreasonably withhold consent to any request for waiver by the other party. Neither party will withhold consent to waiver for any purpose except to protect its own legitimate interests. 

(f) Upon receipt by either party of any subpoena, discovery or other request which arguably calls for the production or disclosure of
information subject to a shared privilege or as to which the other party has the sole right hereunder to assert a privilege, or if a party obtains knowledge that any of its current or former directors, officers, agents or employees has received any
subpoena, discovery or other request which arguably calls for the production or disclosure of such privileged information, such party shall promptly notify the other party of the existence of the request and shall provide the other party a
reasonable opportunity to review the information and to assert any rights it may have under this Section 10 or otherwise to prevent the production or disclosure of such privileged information. 

(g) The transfer of all information pursuant to this Agreement is made in reliance on the parties maintaining the confidentiality of
privileged information and to assert and maintain applicable privileges hereunder. The access to information being granted, the agreement to provide witnesses and individuals and the transfer of privileged information between the parties hereunder
shall not be deemed a waiver of any privilege that has been or may be asserted under this Agreement or otherwise. 

  
 -5- 

 9. Indemnification.

(a) By Cardium. Cardium shall indemnify, defend and hold harmless Angionetics and its affiliates, including each of their respective
directors, officers, employees, representatives and agents (collectively, the “Angionetics Indemnitees”), from and against any and all claims arising out of or resulting from the operation of its businesses, other than the Business
and the specific Assets and Assumed Liabilities that are the subject of the Contribution, whether arising before or after the date of this Agreement; provided, that Cardium shall not be required to indemnify Angionetics for any claim or loss that
arises out of Angionetics’ breach of representation, warranty or covenant of this Agreement, the Shared Services Agreement or any agreement entered into between Cardium and Angionetics after the date hereof. 

(b) By Angionetics. Angionetics shall indemnify, defend and hold harmless Cardium and its affiliates, including each of their
respective directors, officers, employees, representatives and agents (collectively, the “Cardium Indemnitees”), from and against any and all claims arising out of or resulting from the Business, the Assets and the Assumed
Liabilities, whether arising before or after the date of this Agreement; provided, however that Angionetics shall not be required to indemnify Cardium for any claim or loss that arises out of Cardium’s breach of representation, warranty or
covenant of this Agreement, the Shared Services Agreement or any agreement entered into between Cardium and Angionetics after the date hereof. 

(c) Procedures for Third Party Claims. 

(i) If one party (the “Indemnitee”) receives notice or otherwise learns of the assertion against it by a third party
(including any governmental authority) of any claim (a “Third Party Claim”) based upon a duty or obligation alleged to be due by the other party (the “Indemnifying Party”) including without limitation the
obligations of the parties under Section 10 (a) or (b) above, the Indemnitee shall give such Indemnifying Party, written notice thereof as soon as reasonably practicable after becoming aware of such Third Party Claim; provided,
however, that the failure to give the notice shall not relieve the Indemnifying Party of its obligations, except to the extent that such Indemnifying Party is actually prejudiced by such failure. 

(ii) An Indemnifying Party shall defend any Third Party Claim at such Indemnifying Party’s own expense and with such Indemnifying
Party’s own counsel; provided, that if the defendants in any such claim include both the Indemnifying Party and one or more Indemnitees and in such Indemnitees’ reasonable judgment an actual conflict of interest or one is likely to be
asserted between such Indemnitees and such Indemnifying Party in respect of such claim, then such Indemnitees shall have the right to employ separate counsel, in which event the reasonable fees and expenses of such separate counsel (but not more
than one separate counsel for all Indemnitees and in any instance reasonably satisfactory to the Indemnifying Party) shall be paid by the Indemnifying Party. Notwithstanding the foregoing, the Indemnitee shall have the right to employ separate
counsel and to participate in (but not control) the defense, compromise, or settlement thereof in its discretion, but the fees and expenses of such counsel shall be the expense of such Indemnitee. The Indemnifying Party and Indemnitee shall use
commercially reasonable efforts to cause their respective counsel (if applicable), to cooperate fully (in a manner that will preserve all attorney-client privilege or other privileges) to mitigate any such claim and minimize the defense costs
associated therewith. 

  
 -6- 

 (iv) If an Indemnifying Party fails to assume the defense of a Third Party Claim within thirty
(30) days after its receipt of written notice of such claim, upon delivering notice to such effect to the Indemnifying Party, the Indemnitee will have the right to undertake the defense, compromise or settlement of such Third Party Claim on
behalf of and for the account of the Indemnifying Party. In such instance, the Indemnifying Party shall reimburse all out of pocket costs and expenses of the Indemnitee in the event it is ultimately determined that the Indemnifying Party is
obligated to indemnify the Indemnitee with respect to such Third Party Claim. 
 (v) Subrogation. In the event of payment by or on
behalf of any Indemnifying Party to any Indemnitee in connection with any Third Party Claim, such Indemnifying Party shall be subrogated to and shall stand in the place of such Indemnitee as to any events or circumstances in respect of which such
Indemnitee may have any right, defense or claim relating to such Third Party Claim against any claimant or plaintiff asserting such Third Party Claim or against any other person. Such Indemnitee shall cooperate with such Indemnifying Party in a
reasonable manner, and at the cost and expense (including allocated costs of in-house counsel) of such Indemnifying Party, in prosecuting any subrogated right, defense or claim. 

(d) Disclaimer of Representations and Warranties. THE PARTIES EXPRESSLY AGREE THAT THE ASSETS AND THE ASSUMED LIABILITIES ARE BEING
CONTRIBUTED TO ANGIONETICS “AS IS, WHERE IS” WITHOUT REPRESENTATION OR WARRANTY OF ANY KIND. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, CARDIUM MAKES NO REPRESENTATION OR WARRANTY REGARDING THE CONDITION OF THE ASSETS CONTRIBUTED OR
THE LIABILITIES ASSUMED, THE FITNESS OF THE ASSETS FOR A PARTICULAR PURPOSE, TITLE TO THE ASSETS OR THE ABSENCE OF ANY LIENS OR ENCUMBRANCES, THE VALIDITY OR ABILITY TO ENFORCE ANY PATENT RIGHTS, NON-INFRINGEMENT OF THIRD PARTY RIGHTS, THE ABILITY
TO SECURE ANY THIRD PARTY CONSENTS OR GOVERNMENTAL APPROVALS, THE ACCURACY OF INFORMATION IN CONNECTION WITH ANY CLINICAL TRIAL, THE OUTCOME OF ANY CLINICAL TRIAL, OR THE ABILITY TO SUCCESSFULLY COMMERCIALIZE ANY PRODUCT CANDIDATE. 

(e) Insurance. Angionetics agrees to obtain and maintain in effect a policy or policies of insurance relating to products
liability. Such policies shall be issued by one or more reputable insurers, and shall contain reasonable terms of coverage. The minimum amount of coverage under such policies shall be $3 million per occurrence during the commercialization of any
product and $10 million per occurrence after commercial sales begin. Upon the request of Cardium, Angionetics shall provide evidence of insurance coverage in compliance with this Section to Cardium. 

(f) Effect of Insurance. The amount that any Indemnifying Party is required to provide shall be reduced (retroactively or
prospectively) by insurance proceeds or other amounts actually recovered from third parties on behalf of such Indemnitee in respect of the claim or related loss. If an Indemnitee receives a payment as required by this Agreement from an Indemnifying
Party in respect of any claim or related loss and subsequently receives insurance proceeds in respect of such claim or related loss, then such Indemnitee shall hold such insurance proceeds in trust for the benefit of the Indemnifying Party (or
Indemnifying Parties) and shall pay to the Indemnifying Party, as promptly as practicable after receipt, a sum equal to the amount of such insurance proceeds received, up to the aggregate amount of any

  
 -7- 

 
payments received from the Indemnifying Party pursuant to this Agreement. in respect of such claim or loss. 

10. Further Assurances. Cardium and Angionetics agree to execute any and all documents and instruments of transfer, assignment,
assumption or novation and to perform such other acts as may be reasonably necessary or expedient to further the purposes of this Agreement and the transactions contemplated by this Agreement. 

11. Entire Agreement. This Agreement constitutes the sole and entire agreement of the parties to this Agreement with respect to
the subject matter contained herein, and supersedes all prior and contemporaneous understandings, representations and warranties and agreements, both written and oral, with respect to such subject matter. This Agreement may only be amended, modified
or supplemented by an agreement in writing signed by each party hereto. 
 12. Successors and Assigns. This Agreement shall be
binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns. 
 13. No
Third-Party Beneficiaries. This Agreement is for the sole benefit of the parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other person any
legal or equitable right, benefit or remedy of any nature whatsoever, under or by reason of this Agreement. 
 14. Governing Law;
Submission to Jurisdiction. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of
Delaware or any other jurisdiction) that would cause the application of Laws of any jurisdiction other than those of the State of Delaware. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions
contemplated hereby may be instituted in the federal courts of the United States or the Chancery Courts of the State of Delaware, and each party irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action or proceeding.
Service of process, summons, notice or other document by mail to such party’s address set forth herein shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and
unconditionally waive any objection to the laying of venue of any suit, action or any proceeding in such courts and irrevocably waive and agree not to plead or claim in any such court that any such suit, action or proceeding brought in any such
court has been brought in an inconvenient forum. 

  
 -8- 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above
written. 
  

			
	TAXUS CARDIUM PHARMACEUTICALS GROUP, INC.
		
	By:	 	 /s/ CHRISTOPHER J. REINHARD

		 	Christopher J. Reinhard, CEO
	
	ANGIONETICS INC.
		
	By:	 	 /s/ CHRISTOPHER J. REINHARD

		 	Christopher J. Reinhard, CEO

  
 -9- 

 SCHEDULE 1 

Assets Contributed 
  

	 	a)	Receivables: all accounts or notes receivable of the Business; 

  

	 	b)	Inventory: all inventory, finished goods, raw materials, work in progress, packaging, supplies, parts and other inventories of the Generx® product candidate;

  

	 	c)	Contracts: all contracts with product manufacturers, suppliers, clinical research organizations, and distributors related to the Generx® product candidate;
provided however, that Cardium is not transferring any rights or obligations under the agreement with bioRasi, covering the Generx Aspire clinical study which was conducted in the Russian Federation; 

 

	 	d)	Intellectual Property Assets: (1) the trademarks and service marks, including all applications and registrations and the goodwill connected with the use of and symbolized by the foregoing related to Generx®; (2) copyrights, including all applications and registrations, and works of authorship, whether or not copyrightable related to
Generx®; (3) trade secrets and confidential know-how related to Generx®; (4) patents and patent applications related to
Generx®; (5) websites related to the Generx® product candidate and internet domain name registrations for
www.angionetics.com; and (6) the license rights under the following agreements: 

  

	 	•	 	Technology Transfer Agreement effective as of October 13, 2005, by and among Schering AG, Berlex, Inc., Collateral Therapeutics, Inc. and Cardium Therapeutics, Inc. 

 

	 	e)	Regulatory permits, records, licenses, approvals or rights necessary to operate and advance the Business according to the business plan and to commercialized Generx, but only to the extent such permits may be
transferred under applicable law including without limitation the original FDA IND Submission, all IND Amendments to FDA (includes Annual Reports, Clinical Study Reports, Clinical Study Protocols, Investigator Brochures, Investigator CVs, End of
Phase 2 pre-meeting Submission, End of Phase 2 Meeting Minutes), and Telecommunication Records; 

  

	 	f)	Deposits: all prepaid expenses, credits, advance payments, security, deposits, charges, sums and fees, if any to the extent related to any Asset; 

 

	 	g)	Contract and Warranty Claims: all of Cardium’s rights under warranties, indemnities and all similar rights against third parties to the extent related to any Assets; 

 

	 	h)	Litigation Claims: all rights to any action, suit or claim of any nature available to or being pursued by Cardium, whether arising by way of counterclaim or otherwise that relate to Generx®, the Assets or the Business; provided, however, that Cardium is not transferring and is specifically retaining all claims and counterclaims related to the dispute between Cardium and bioRASI,
arising out of the Generx Aspire clinical study which was conducted in the Russian Federation; 

  
 -10- 

	 	i)	Books and Records: originals, or where not available, copies, of all books and records, including books of account, ledgers and general, financial and accounting records, production data, quality control records and
procedures, research and development files, clinical trial records and data (including all correspondence with any Governmental Authority), sales material and records, strategic plans, internal financial statements and marketing and promotional
surveys, material and research, that exclusively relate to the Business or the Assets; 

  

	 	j)	All assets related to manufacturing and controls including without limitation Ad5FGF-4 Master Virus Bank (frozen), HEK 293 Producer Cell Bank (frozen), Developmental histories and lineages for Master Virus Bank and
Master Cell Bank, Ad5FGF-4 Genomic Sequence, Ad5FGF-4 Batch Production Records, Placebo (Ad5FGF-4 formulation buffer) Production Records, Product (Lot release) Testing Protocols and specifications, Product release testing reports, Product release
Certificates of Analysis, and Stability; 

  

	 	k)	All information and records pertaining to pre-clinical and clinical studies of Generx including without limitation study protocols, reports, safety data and summaries, follow-up records, individual patient listings and
data tables, clinical data statistical analyses, instructions for drug preparation prior to administration, and training Videos (including drug administration); 

  

	 	l)	Quality Systems records and standard operating procedures including Clinical Standard Operating Procedures (SOPs), Regulatory SOPs, and CMC SOPs; and 

 

	 	m)	Goodwill: all goodwill associated with any of the Assets described in the foregoing clauses. 

  
 -11- 

 Schedule 2 

Assumed Liabilities 
  

							
	 	  	Angionetics
Liability
	 Allocated accrued (unpaid) employee compensation (August 2015 - May 2016):
	  	$	 465,250	  	 	(A)
	 Allocated Employee benefits paid by Cardium (August 2015 - May 2016):
	  	$	 106,000	  	 	(B)
	 Zhang Consulting Services:
	  	$	 150,000	  	 	
	 Allocated expenses paid by Cardium on behalf of Angionetics (August 2015 - May
2016):
	  	 	268,850	  	 	(C)
	 Generx related assumed vendor liabilities:
	  	 	236,760	  	 	(D)
	 Generx related assumed Professional Fees (Audit, Legal, Tax):
	  	 	267,540	  	 	(E)
		  	  
	  
	 	 	
	 Total
	  	 	923,150	  	 	(F)
		  	  
	  
	 	 	

 Footnotes: 
  

	 	-	 	(A), (B), (C), additional detail set forth on Schedule 2.1. As set forth in Section 3.14 of the Disclosure Schedule, the amounts in (A) and (B) would be paid 50% ($285,625) following completion of the
planned mezzanine financing and 50% ($285,625) would be paid following completion of the planned IPO. The amounts in (C) ($268,850) would be paid following completion of the planned IPO. 

	 	-	 	(D) Break out set forth on Schedule 2.2 

	 	-	 	(E) Break out set forth on Schedule 2.2 

	 	-	 	(F) $500,000 to be paid pursuant to the advance against the Technology Fee pursuant to the Securities Purchase Agreement, with the balance to be paid following the closing of the IPO. 

  
 -12- 

 Angionetics Inc. 

Schedule 2.1 
 Statement
of Operations (1) 
 Since Formation on July 29, 2015 

 

																							
	 	  	2015	 	  	2016	 	  	Formation
to May 30,
2016	 	 	 
	 	  	2 mos Q3	 	  	Q4	 	  	Q1	 	  	2mos Q2	 	  	Total	 	 	 
	 Employee Compensation/benefits
	  	$	93,050	  	  	$	139,576	  	  	$	139,576	  	  	$	93,050	  	  	$	465,252	  	 	(A)
	 Employee benefits and “er” payroll taxes
	  	 	21,200	  	  	 	31,800	  	  	 	31,800	  	  	 	21,200	  	  	 	106,000	  	 	(B)
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	 	
	 Subtotal
	  	$	114,250	  	  	$	171,376	  	  	$	171,376	  	  	$	114,250	  	  	$	571,252	  	 	
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	 	
	 Office Rent Expense
	  	 	16,102	  	  	 	24,153	  	  	 	25,506	  	  	 	17,004	  	  	 	82,764	  	 	
	 Insurances
	  	 	17,208	  	  	 	25,813	  	  	 	25,805	  	  	 	17,203	  	  	 	86,029	  	 	
	 Office Expenses
	  	 	6,928	  	  	 	10,392	  	  	 	10,500	  	  	 	7,000	  	  	 	34,820	  	 	
	 Consulting Services
	  	 	9,891	  	  	 	17,837	  	  	 	10,689	  	  	 	7,126	  	  	 	45,544	  	 	
	 Information Services
	  	 	3,938	  	  	 	5,906	  	  	 	5,911	  	  	 	3,941	  	  	 	19,695	  	 	
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	 	
	 Subtotal
	  	 	54,067	  	  	 	84,101	  	  	 	78,410	  	  	 	52,274	  	  	 	268,852	  	 	(C)
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	 	
	 Loss from Operations
	  	 	168,318	  	  	$	255,476	  	  	$	249,786	  	  	$	166,524	  	  	$	840,104	  	 	
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	 	

  

	 	-	 	(1) Allocated from Cardium (unaudited) 

	 	-	 	Does not include Audit or legal fees 

	 	-	 	Does not include Technology access fees from UC Regents or NYU. 

	 	-	 	Does not include Generx Storage fees included in assumed vendor liabilities 

  
 -13- 

 Angionetics Inc. 

Schedule 2.2 
 Assumed
Generx Accounts Payables 
 as of 5/30/16 
  

							
	 	  	Angionetics	 	 	 
	 	  	Payables	 	 	 
	 Essen BioScience
	  	$	5,400	  	 	
	 PR Newswire
	  	 	6,521	  	 	
	 Bioserv Corporation
	  	 	6,750	  	 	
	 Cedars-Sinai Medical Center
	  	 	7,863	  	 	
	 San Diego County Treasurer - Tax Coll.
	  	 	8,647	  	 	
	 Investor Relations Angionetics
	  	 	20,000	  	 	
	 New York University (research)
	  	 	35,000	  	 	
	 Company credit card
	  	 	20,000	  	 	
	 SAFC Pharma
	  	 	61,000	  	 	
	 Misc. vendors<$5000
	  	 	5,588	  	 	
	 RR Donnelley Receivables
	  	 	59,989	  	 	
		  	  
	  
	 	 	
	 Subtotal Vendors
	  	 	236,758	  	 	(D)
		  	  
	  
	 	 	
	 L. Scott Shields & Associates
	  	 	6,700	  	 	
	 Marcum Kleigman (audit firm)
	  	 	110,843	  	 	
	 Sheppard Mullin Richter & Hampton LLP
	  	 	150,000	  	 	
		  	  
	  
	 	 	
	 Subtotal Professional Fees
	  	 	267,543	  	 	(E)
		  	  
	  
	 	 	
	 Total Assumed Accounts Payable
	  	$	504,301	  	 	
		  	  
	  
	 	 	

  
 -14- 

 Angionetics Inc. 

Schedule 2.3 
 Additional
assumed liabilities 
 (a) all liabilities and obligations arising under or relating to the contracts, intellectual property rights or other Assets; and

 (b) all other liabilities and obligations arising out of or relating to the ownership or operation of the Business and the Assets on or after the date of
this Agreement. 

  
 -15-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}]]